|
G |
Ache |
acetylcholinesterase |
affects activity |
EXP |
mancozeb affects the activity of ACHE protein |
CTD |
PMID:10641187 |
|
NCBI chr12:22,472,358...22,477,052
Ensembl chr12:22,472,358...22,478,753
|
|
G |
Actg1 |
actin, gamma 1 |
increases expression |
ISO |
mancozeb results in increased expression of ACTG1 protein |
CTD |
PMID:21375462 |
|
NCBI chr10:109,518,429...109,521,288
Ensembl chr 3:75,643,054...75,644,954 Ensembl chr10:75,643,054...75,644,954
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] affects the phosphorylation of AKT1 protein; [alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in decreased expression of AKT1 protein |
CTD |
PMID:19883720 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Alb |
albumin |
decreases expression |
ISO |
mancozeb results in decreased expression of ALB protein |
CTD |
PMID:21375462 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
decreases activity |
EXP |
mancozeb results in decreased activity of ALDH2 protein |
CTD |
PMID:17010440 |
|
NCBI chr12:40,466,418...40,498,813
Ensembl chr12:40,466,495...40,498,752
|
|
G |
Aldh5a1 |
aldehyde dehydrogenase 5 family, member A1 |
decreases activity |
EXP |
mancozeb results in decreased activity of ALDH5A1 protein |
CTD |
PMID:17010440 |
|
NCBI chr17:42,133,076...42,159,413
Ensembl chr17:42,133,076...42,159,413
|
|
G |
Anxa2 |
annexin A2 |
decreases expression |
ISO |
mancozeb results in decreased expression of ANXA2 protein |
CTD |
PMID:21375462 |
|
NCBI chr 8:75,687,134...75,723,589
Ensembl chr 8:75,687,100...75,723,594
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
increases expression |
ISO |
mancozeb results in increased expression of APAF1 protein |
CTD |
PMID:22289270 |
|
NCBI chr 7:31,699,309...31,784,192
Ensembl chr 7:31,699,885...31,784,192
|
|
G |
Ar |
androgen receptor |
multiple interactions decreases activity |
ISO |
mancozeb inhibits the reaction [Dihydrotestosterone binds to and results in increased activity of AR protein]; mancozeb inhibits the reaction [Metribolone binds to and results in increased activity of AR protein] mancozeb results in decreased activity of AR protein |
CTD |
PMID:23871939 |
|
NCBI chr X:67,656,253...67,828,998
Ensembl chr X:67,656,253...67,829,026
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
ISO |
mancozeb results in increased expression of BAX mRNA; mancozeb results in increased expression of BAX protein lupeol inhibits the reaction [mancozeb results in increased expression of BAX mRNA] |
CTD |
PMID:22289270 PMID:27235710 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO EXP |
mancozeb results in decreased expression of BCL2 mRNA; mancozeb results in decreased expression of BCL2 protein lupeol inhibits the reaction [mancozeb results in decreased expression of BCL2 mRNA] alpha-Tocopherol inhibits the reaction [mancozeb results in decreased expression of BCL2 protein] |
CTD |
PMID:16005924 PMID:22289270 PMID:27235710 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Ca3 |
carbonic anhydrase 3 |
increases expression |
ISO |
mancozeb results in increased expression of CAR3 protein |
CTD |
PMID:21375462 |
|
NCBI chr 2:88,126,519...88,136,063
Ensembl chr 2:88,126,667...88,135,410
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions increases cleavage |
ISO |
mancozeb results in increased activity of CASP3 protein Acetylcysteine inhibits the reaction [mancozeb results in increased cleavage of CASP3 protein] mancozeb results in increased cleavage of and results in increased activity of CASP3 protein |
CTD |
PMID:22289270 PMID:22824503 PMID:30037311 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp7 |
caspase 7 |
increases activity |
ISO |
mancozeb results in increased activity of CASP7 protein |
CTD |
PMID:22824503 |
|
NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
|
|
G |
Casp8 |
caspase 8 |
increases activity |
ISO |
mancozeb results in increased activity of CASP8 protein |
CTD |
PMID:22289270 PMID:22824503 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
increases activity multiple interactions |
ISO |
mancozeb results in increased activity of CASP9 protein mancozeb results in increased cleavage of and results in increased activity of CASP9 protein |
CTD |
PMID:22289270 PMID:22824503 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cat |
catalase |
multiple interactions decreases activity |
ISO EXP |
Acetylcysteine inhibits the reaction [mancozeb results in decreased activity of CAT protein]; lupeol inhibits the reaction [mancozeb results in decreased activity of CAT protein]; Quercetin inhibits the reaction [mancozeb results in decreased activity of CAT protein] Colforsin inhibits the reaction [mancozeb results in decreased activity of CAT protein] |
CTD |
PMID:23024109 PMID:27235710 PMID:29283200 PMID:30037311 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions increases expression |
ISO |
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in increased expression of CCND1 protein mancozeb results in increased expression of CCND1 protein |
CTD |
PMID:19883720 PMID:21375462 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Cdc25c |
cell division cycle 25C |
increases phosphorylation |
ISO |
mancozeb results in increased phosphorylation of CDC25C protein |
CTD |
PMID:21375462 |
|
NCBI chr18:27,528,768...27,550,316
Ensembl chr18:27,528,354...27,550,224
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO |
lupeol inhibits the reaction [mancozeb results in increased expression of CDKN1A mRNA] |
CTD |
PMID:27235710 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cycs |
cytochrome c, somatic |
increases expression |
ISO |
mancozeb results in increased expression of CYCS protein |
CTD |
PMID:27016407 |
|
NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity decreases expression |
EXP ISO |
mancozeb results in decreased activity of CYP1A1 protein mancozeb results in decreased expression of CYP1A1 protein |
CTD |
PMID:1946188 PMID:31096615 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
decreases expression |
ISO |
mancozeb results in decreased expression of CYP2B6 protein |
CTD |
PMID:31096615 |
|
NCBI chr 1:83,163,103...83,236,615
Ensembl chr 1:83,163,079...83,236,615
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases expression |
ISO |
mancozeb results in decreased expression of CYP2E1 mRNA |
CTD |
PMID:31096615 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
decreases expression |
ISO |
mancozeb results in decreased expression of CYP3A4 mRNA; mancozeb results in decreased expression of CYP3A4 protein |
CTD |
PMID:31096615 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
increases expression |
EXP |
mancozeb results in increased expression of DDIT4 protein |
CTD |
PMID:24764117 |
|
NCBI chr20:29,509,283...29,511,382
Ensembl chr20:29,509,289...29,511,382
|
|
G |
Elk1 |
ETS transcription factor ELK1 |
increases phosphorylation |
ISO |
mancozeb results in increased phosphorylation of ELK1 protein |
CTD |
PMID:21375462 |
|
NCBI chr X:1,287,875...1,304,822
Ensembl chr X:1,297,099...1,304,822
|
|
G |
F3 |
coagulation factor III, tissue factor |
increases expression |
ISO |
mancozeb results in increased expression of F3 protein |
CTD |
PMID:25569083 |
|
NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
mancozeb results in increased expression of FAS protein |
CTD |
PMID:22289270 |
|
NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
|
|
G |
Faslg |
Fas ligand |
increases expression |
ISO |
mancozeb results in increased expression of FASLG protein |
CTD |
PMID:22289270 |
|
NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
multiple interactions increases expression |
ISO |
lupeol inhibits the reaction [mancozeb results in increased expression of GADD45A mRNA] |
CTD |
PMID:27235710 |
|
NCBI chr 4:97,782,512...97,784,814
Ensembl chr 4:97,782,512...97,784,842
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
affects activity |
EXP |
mancozeb affects the activity of GOT1 protein |
CTD |
PMID:10641187 |
|
NCBI chr 1:263,246,248...263,269,762
Ensembl chr 1:263,246,248...263,269,762
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
affects activity |
EXP |
mancozeb affects the activity of GPT protein |
CTD |
PMID:10641187 |
|
NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
decreases expression multiple interactions |
ISO |
mancozeb results in decreased expression of GPX1 mRNA Acetylcysteine inhibits the reaction [mancozeb results in decreased expression of GPX1 mRNA] |
CTD |
PMID:30037311 |
|
NCBI chr 8:117,117,430...117,118,528
Ensembl chr 8:117,117,430...117,118,522
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
ISO |
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] affects the phosphorylation of GSK3B protein |
CTD |
PMID:19883720 |
|
NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
|
|
G |
Hdac3 |
histone deacetylase 3 |
decreases activity |
ISO |
mancozeb results in decreased activity of HDAC3 protein |
CTD |
PMID:21251949 |
|
NCBI chr18:31,073,057...31,094,347
Ensembl chr18:31,073,058...31,094,303
|
|
G |
Hdac6 |
histone deacetylase 6 |
decreases activity |
ISO |
mancozeb results in decreased activity of HDAC6 protein |
CTD |
PMID:21251949 |
|
NCBI chr X:15,295,372...15,316,673
Ensembl chr X:15,295,473...15,316,671
|
|
G |
Hnrnpm |
heterogeneous nuclear ribonucleoprotein M |
increases expression |
ISO |
mancozeb results in increased expression of HNRNPM protein |
CTD |
PMID:21375462 |
|
NCBI chr 7:18,516,253...18,554,536
Ensembl chr 7:18,516,512...18,554,227
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
mancozeb affects the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased secretion of TNF protein] |
CTD |
PMID:15742816 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
mancozeb inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein] |
CTD |
PMID:16112155 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il2 |
interleukin 2 |
affects expression |
ISO |
mancozeb affects the expression of IL2 protein |
CTD |
PMID:9012323 |
|
NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
|
|
G |
Kb15 |
type II keratin Kb15 |
decreases expression |
ISO |
mancozeb results in decreased expression of KRT6A protein |
CTD |
PMID:21375462 |
|
NCBI chr 7:143,208,034...143,217,771
Ensembl chr 7:143,208,527...143,217,535
|
|
G |
Kcnq2 |
potassium voltage-gated channel subfamily Q member 2 |
increases activity |
EXP |
mancozeb results in increased activity of KCNQ2 protein |
CTD |
PMID:23542819 |
|
NCBI chr 3:176,585,897...176,645,029
Ensembl chr 3:176,589,906...176,644,951
|
|
G |
Kiss1 |
KiSS-1 metastasis-suppressor |
affects expression |
EXP |
mancozeb affects the expression of KISS1 mRNA |
CTD |
PMID:23660487 |
|
NCBI chr13:50,529,506...50,537,603
Ensembl chr13:50,529,510...50,535,389
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [mancozeb results in increased activity of MAPK1 protein]; mancozeb results in increased localization of and results in increased activity of MAPK1 protein |
CTD |
PMID:21375462 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [mancozeb results in increased activity of MAPK3 protein]; mancozeb results in increased localization of and results in increased activity of MAPK3 protein |
CTD |
PMID:21375462 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
multiple interactions increases expression |
ISO |
lupeol inhibits the reaction [mancozeb results in increased expression of MDM2 mRNA] |
CTD |
PMID:27235710 |
|
NCBI chr 7:60,719,060...60,743,618
Ensembl chr 7:60,719,066...60,743,328
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions increases expression decreases expression |
ISO EXP |
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in increased expression of MYC protein mancozeb results in increased expression of MYC protein mancozeb results in decreased expression of MYC protein alpha-Tocopherol inhibits the reaction [mancozeb results in decreased expression of MYC protein] |
CTD |
PMID:16005924 PMID:19883720 |
|
NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression multiple interactions |
ISO |
mancozeb results in increased expression of NOS2 mRNA Acetylcysteine inhibits the reaction [mancozeb results in increased expression of NOS2 mRNA] |
CTD |
PMID:30037311 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nox4 |
NADPH oxidase 4 |
multiple interactions increases expression |
ISO |
Acetylcysteine inhibits the reaction [mancozeb results in increased expression of NOX4 mRNA] |
CTD |
PMID:30037311 |
|
NCBI chr 1:150,796,359...150,976,186
Ensembl chr 1:150,797,084...150,976,194
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
increases activity |
ISO |
mancozeb results in increased activity of ODC1 protein |
CTD |
PMID:1733566 |
|
NCBI chr 6:42,852,529...42,859,142
Ensembl chr 6:42,852,683...42,859,927
|
|
G |
Ogg1 |
8-oxoguanine DNA glycosylase |
multiple interactions decreases expression |
ISO |
lupeol inhibits the reaction [mancozeb results in decreased expression of OGG1 mRNA] |
CTD |
PMID:27235710 |
|
NCBI chr 4:145,282,828...145,289,367
Ensembl chr 4:145,282,797...145,289,326
|
|
G |
Prdx2 |
peroxiredoxin 2 |
increases expression |
ISO |
mancozeb results in increased expression of PRDX2 protein |
CTD |
PMID:21375462 |
|
NCBI chr19:26,084,816...26,090,095
Ensembl chr19:26,084,903...26,090,094
|
|
G |
Prl |
prolactin |
multiple interactions |
ISO |
[mancozeb co-treated with imidacloprid] results in increased expression of PRL protein |
CTD |
PMID:24530807 |
|
NCBI chr17:39,814,236...39,824,299
Ensembl chr17:39,814,244...39,824,299
|
|
G |
Ptges |
prostaglandin E synthase |
increases expression multiple interactions |
ISO |
mancozeb results in increased expression of PTGES mRNA lupeol inhibits the reaction [mancozeb results in increased expression of PTGES mRNA] |
CTD |
PMID:27235710 |
|
NCBI chr 3:9,727,408...9,738,752
Ensembl chr 3:9,727,408...9,738,752
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
ISO |
mancozeb results in increased expression of PTGS2 protein |
CTD |
PMID:21375462 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Ptk2b |
protein tyrosine kinase 2 beta |
multiple interactions |
ISO |
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in decreased expression of PTK2B protein modified form |
CTD |
PMID:19883720 |
|
NCBI chr15:42,827,306...42,947,796
Ensembl chr15:42,827,310...42,947,656
|
|
G |
Pvalb |
parvalbumin |
increases expression |
ISO |
mancozeb results in increased expression of PVALB protein |
CTD |
PMID:21375462 |
|
NCBI chr 7:119,428,657...119,443,674
Ensembl chr 7:119,429,019...119,441,487
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
increases phosphorylation affects localization multiple interactions increases localization |
ISO |
mancozeb results in increased phosphorylation of RELA protein mancozeb affects the localization of RELA protein Acetylcysteine inhibits the reaction [mancozeb affects the localization of RELA protein]; lupeol inhibits the reaction [mancozeb affects the localization of RELA protein]; mancozeb inhibits the reaction [Lipopolysaccharides affects the localization of and results in increased activity of RELA protein] mancozeb results in increased localization of RELA protein |
CTD |
PMID:16112155 PMID:21375462 PMID:22289270 PMID:27235710 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
S100a6 |
S100 calcium binding protein A6 |
increases expression |
ISO |
mancozeb results in increased expression of S100A6 protein |
CTD |
PMID:21375462 |
|
NCBI chr 2:190,007,013...190,008,512
Ensembl chr 2:190,007,216...190,008,511
|
|
G |
S100a9 |
S100 calcium binding protein A9 |
increases expression |
ISO |
mancozeb results in increased expression of S100A9 protein |
CTD |
PMID:21375462 |
|
NCBI chr 2:190,097,436...190,100,209
Ensembl chr 2:190,097,554...190,100,276
|
|
G |
Sirt1 |
sirtuin 1 |
decreases activity |
ISO |
mancozeb results in decreased activity of SIRT1 protein |
CTD |
PMID:21251949 |
|
NCBI chr20:26,831,971...26,851,587
Ensembl chr20:26,833,357...26,852,199
|
|
G |
Sirt2 |
sirtuin 2 |
decreases activity |
ISO |
mancozeb results in decreased activity of SIRT2 protein |
CTD |
PMID:21251949 |
|
NCBI chr 1:86,948,866...86,971,954
Ensembl chr 1:86,948,918...86,971,952
|
|
G |
Sirt3 |
sirtuin 3 |
decreases activity |
ISO |
mancozeb results in decreased activity of SIRT3 protein |
CTD |
PMID:21251949 |
|
NCBI chr 1:213,613,502...213,636,061
Ensembl chr 1:213,613,513...213,635,546
|
|
G |
Slc5a5 |
solute carrier family 5 member 5 |
multiple interactions |
ISO |
mancozeb inhibits the reaction [SLC5A5 protein results in increased uptake of Iodine] |
CTD |
PMID:27979590 |
|
NCBI chr16:20,297,414...20,307,401
Ensembl chr16:20,297,414...20,307,400
|
|
G |
Sod1 |
superoxide dismutase 1 |
decreases expression |
ISO |
mancozeb results in decreased expression of SOD1 protein |
CTD |
PMID:21375462 |
|
NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
|
|
G |
Tek |
TEK receptor tyrosine kinase |
increases activity |
ISO |
mancozeb results in increased activity of TEK protein |
CTD |
PMID:21251949 |
|
NCBI chr 5:113,725,717...113,852,799
Ensembl chr 5:113,725,717...113,852,799
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
mancozeb affects the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased secretion of TNF protein] mancozeb inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; mancozeb inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; mancozeb inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of TNF protein] |
CTD |
PMID:15742816 PMID:15893782 PMID:16112155 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tp53 |
tumor protein p53 |
decreases expression increases expression multiple interactions |
ISO |
mancozeb results in decreased expression of TRP53 mRNA; mancozeb results in decreased expression of TRP53 protein mancozeb results in increased expression of TP53 mRNA lupeol inhibits the reaction [mancozeb results in increased expression of TP53 mRNA] |
CTD |
PMID:22369882 PMID:27235710 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Tpi1 |
triosephosphate isomerase 1 |
increases expression |
ISO |
mancozeb results in increased expression of TPI1 protein |
CTD |
PMID:21375462 |
|
NCBI chr 4:157,328,375...157,331,905
Ensembl chr 4:157,328,379...157,331,905
|
|
G |
Tpo |
thyroid peroxidase |
decreases activity |
EXP |
mancozeb results in decreased activity of TPO protein |
CTD |
PMID:9418944 |
|
NCBI chr 6:49,020,918...49,089,855
Ensembl chr 6:49,021,044...49,089,855
|
|
G |
Tshb |
thyroid stimulating hormone subunit beta |
multiple interactions |
ISO |
[mancozeb co-treated with imidacloprid] results in increased expression of TSHB protein |
CTD |
PMID:24530807 |
|
NCBI chr 2:205,207,799...205,215,199
Ensembl chr 2:205,207,799...205,212,681
|
|
G |
Xrcc1 |
X-ray repair cross complementing 1 |
decreases expression multiple interactions |
ISO |
mancozeb results in decreased expression of XRCC1 mRNA lupeol inhibits the reaction [mancozeb results in decreased expression of XRCC1 mRNA] |
CTD |
PMID:27235710 |
|
NCBI chr 1:81,412,635...81,441,680
Ensembl chr 1:81,413,353...81,441,678
|
|
|
G |
Acads |
acyl-CoA dehydrogenase short chain |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of ACADS mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ACADS mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ACADS mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr12:47,254,503...47,263,747
Ensembl chr12:47,254,484...47,263,747
|
|
G |
Ache |
acetylcholinesterase |
decreases expression multiple interactions |
EXP ISO |
Maneb results in decreased expression of ACHE protein [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of ACHE mRNA |
CTD |
PMID:3868355 PMID:23017109 |
|
NCBI chr12:22,472,358...22,477,052
Ensembl chr12:22,472,358...22,478,753
|
|
G |
Aco2 |
aconitase 2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of ACO2 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 7:123,102,493...123,145,608
Ensembl chr 7:123,102,468...123,145,635
|
|
G |
Adam22 |
ADAM metallopeptidase domain 22 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of ADAM22 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 4:22,864,485...23,002,969
Ensembl chr 4:22,859,622...22,996,645
|
|
G |
Adgrb1 |
adhesion G protein-coupled receptor B1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of ADGRB1 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 7:115,766,484...115,828,514
|
|
G |
Adgrg1 |
adhesion G protein-coupled receptor G1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of ADGRG1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr19:10,423,534...10,460,674
Ensembl chr19:10,423,501...10,460,674
|
|
G |
Adora1 |
adenosine A1 receptor |
multiple interactions |
ISO |
[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of ADORA1 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr13:51,042,111...51,076,913
Ensembl chr13:51,042,248...51,076,852
|
|
G |
Ago3 |
argonaute RISC catalytic component 3 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of AGO3 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 5:144,355,792...144,436,509
Ensembl chr 5:144,364,269...144,436,509
|
|
G |
Aif1 |
allograft inflammatory factor 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of AIF1 protein; [Paraquat co-treated with Maneb] results in increased expression of AIF1 protein; acetovanillone inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of AIF1 protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of AIF1 protein] |
CTD |
PMID:28202386 PMID:32375810 |
|
NCBI chr20:5,161,350...5,167,176
Ensembl chr20:5,161,333...5,166,448
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of AKR1B3 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 4:61,706,866...61,720,959
Ensembl chr 4:61,706,864...61,720,956
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] affects the phosphorylation of AKT1 protein; [alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in decreased expression of AKT1 protein; [Maneb co-treated with Paraquat] results in decreased expression of AKT1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of AKT1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of AKT1 mRNA] |
CTD |
PMID:19883720 PMID:23963992 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Alas2 |
5'-aminolevulinate synthase 2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of ALAS2 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr X:23,167,576...23,187,356
Ensembl chr X:23,167,696...23,187,341
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
decreases activity |
EXP |
Maneb results in decreased activity of ALDH2 protein |
CTD |
PMID:17010440 |
|
NCBI chr12:40,466,418...40,498,813
Ensembl chr12:40,466,495...40,498,752
|
|
G |
Aldh5a1 |
aldehyde dehydrogenase 5 family, member A1 |
decreases activity multiple interactions |
EXP ISO |
Maneb results in decreased activity of ALDH5A1 protein [Maneb co-treated with Paraquat] results in decreased expression of ALDH5A1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ALDH5A1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ALDH5A1 mRNA] |
CTD |
PMID:17010440 PMID:23963992 |
|
NCBI chr17:42,133,076...42,159,413
Ensembl chr17:42,133,076...42,159,413
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of ALDOC mRNA |
CTD |
PMID:18386188 |
|
NCBI chr10:65,586,504...65,590,093
Ensembl chr10:65,586,504...65,590,126
|
|
G |
Amn |
amnion associated transmembrane protein |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of AMN mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 6:135,724,455...135,731,896
Ensembl chr 6:135,724,455...135,731,896
|
|
G |
Ap3b2 |
adaptor related protein complex 3 subunit beta 2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of AP3B2 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 1:143,284,041...143,315,846
Ensembl chr 1:143,283,996...143,315,633
|
|
G |
Ap3d1 |
adaptor related protein complex 3 subunit delta 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of AP3D1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 7:11,838,639...11,873,992
Ensembl chr 7:11,838,639...11,873,984
|
|
G |
Apbb1 |
amyloid beta precursor protein binding family B member 1 |
multiple interactions |
ISO |
[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of APBB1 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 1:170,387,625...170,411,263
Ensembl chr 1:170,387,609...170,404,056
|
|
G |
Arf3 |
ADP-ribosylation factor 3 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of ARF3 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 7:140,412,463...140,438,751
Ensembl chr 7:140,398,199...140,437,467
|
|
G |
Arg1 |
arginase 1 |
decreases expression multiple interactions |
ISO |
Maneb results in decreased expression of ARG1 mRNA [Paraquat co-treated with Maneb] results in increased expression of ARG1 mRNA |
CTD |
PMID:29568078 PMID:32194361 PMID:32375810 |
|
NCBI chr 1:21,525,421...21,537,872
Ensembl chr 1:21,525,421...21,537,863
|
|
G |
Arnt2 |
aryl hydrocarbon receptor nuclear translocator 2 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of ARNT2 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 1:146,399,217...146,556,437
Ensembl chr 1:146,399,217...146,556,171
|
|
G |
Ascl1 |
achaete-scute family bHLH transcription factor 1 |
multiple interactions |
ISO |
[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of ASCL1 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 7:28,038,662...28,040,504
Ensembl chr 7:28,038,662...28,040,510
|
|
G |
Atg12 |
autophagy related 12 |
multiple interactions |
ISO |
Maneb promotes the reaction [Paraquat results in increased expression of ATG12 protein] |
CTD |
PMID:22292029 |
|
NCBI chr18:40,721,799...40,732,143
Ensembl chr18:40,721,800...40,732,126
|
|
G |
Atp5f1a |
ATP synthase F1 subunit alpha |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of ATP5A1 protein; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ATP5A1 protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ATP5A1 protein] |
CTD |
PMID:23562983 |
|
NCBI chr18:74,156,553...74,164,490
Ensembl chr18:74,156,553...74,164,495
|
|
G |
Atp5mc1 |
ATP synthase membrane subunit c locus 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of ATP5G1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr10:83,895,941...83,898,640
Ensembl chr10:83,895,947...83,898,527
|
|
G |
Atp6v0b |
ATPase H+ transporting V0 subunit B |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of ATP6V0B mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 5:136,718,352...136,719,868
Ensembl chr 5:136,718,352...136,721,379
|
|
G |
Atp6v0c |
ATPase H+ transporting V0 subunit C |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of ATP6V0C mRNA |
CTD |
PMID:18386188 |
|
NCBI chr10:13,537,031...13,543,407
Ensembl chr10:13,537,033...13,542,077
|
|
G |
Atp6v1c1 |
ATPase H+ transporting V1 subunit C1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of ATP6V1C1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ATP6V1C1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ATP6V1C1 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 7:77,678,853...77,716,658
Ensembl chr 7:77,678,968...77,716,408
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased phosphorylation of BAD protein |
CTD |
PMID:15824117 |
|
NCBI chr 1:222,198,516...222,207,459
Ensembl chr 1:222,198,534...222,207,453
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
multiple interactions increases expression affects response to substance |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of BAK1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of BAK1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of BAK1 mRNA] [Paraquat co-treated with Maneb] results in increased expression of BAK1 protein; Maneb inhibits the reaction [BAK1 protein affects the susceptibility to Paraquat]; Paraquat inhibits the reaction [BAK1 protein affects the susceptibility to Maneb] Maneb results in increased expression of BAK1 mRNA; Maneb results in increased expression of BAK1 protein |
CTD |
PMID:18266926 PMID:23963992 |
|
NCBI chr20:5,609,620...5,618,899
Ensembl chr20:5,609,625...5,618,260
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of BAX protein; BAX protein affects the susceptibility to [Paraquat co-treated with Maneb] Maneb results in increased expression of BAX protein [Maneb co-treated with Paraquat] results in increased expression of BAX mRNA; [Paraquat co-treated with Maneb] results in increased expression of BAX protein; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of BAX mRNA]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of BAX protein]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of BAX mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of BAX protein] |
CTD |
PMID:15824117 PMID:18266926 PMID:20964710 PMID:23963992 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
increases expression |
ISO |
Maneb results in increased expression of BBC3 protein |
CTD |
PMID:18266926 |
|
NCBI chr 1:78,261,491...78,267,802
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions increases expression |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of BCL2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of BCL2 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of BCL2 mRNA] Maneb results in increased expression of BCL2 mRNA; Maneb results in increased expression of BCL2 protein |
CTD |
PMID:18266926 PMID:23963992 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bcl2a1 |
BCL2-related protein A1 |
increases expression multiple interactions |
ISO |
Maneb results in increased expression of BCL2A1 mRNA [Paraquat co-treated with Maneb] results in increased expression of BCL2A1 protein |
CTD |
PMID:18266926 |
|
NCBI chr 8:96,551,424...96,559,527
Ensembl chr 8:96,551,245...96,559,483
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions increases expression |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of BCL2L1 protein Maneb results in increased expression of BCL2L1 mRNA |
CTD |
PMID:15824117 PMID:18266926 |
|
NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
|
|
G |
Bcl2l11 |
BCL2 like 11 |
increases expression multiple interactions |
ISO |
Maneb results in increased expression of BCL2L11 protein [Paraquat co-treated with Maneb] results in increased expression of BCL2L11 protein |
CTD |
PMID:18266926 |
|
NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
ISO EXP |
[Maneb co-treated with Paraquat] results in decreased expression of BDNF mRNA [Paraquat co-treated with Maneb] results in decreased expression of BDNF mRNA; [Paraquat co-treated with Maneb] results in decreased expression of BDNF protein |
CTD |
PMID:23017109 PMID:27460631 |
|
NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
|
|
G |
Becn1 |
beclin 1 |
increases expression multiple interactions |
ISO |
Maneb results in increased expression of BECN1 protein [Paraquat co-treated with Maneb] results in increased expression of BECN1 protein |
CTD |
PMID:22292029 PMID:26884967 |
|
NCBI chr10:89,209,944...89,225,297
Ensembl chr10:89,209,940...89,225,297
|
|
G |
Bicd1 |
BICD cargo adaptor 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of BICD1 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 4:184,018,845...184,167,628
Ensembl chr 4:184,019,087...184,165,540
|
|
G |
Bid |
BH3 interacting domain death agonist |
increases expression multiple interactions |
ISO |
Maneb results in increased expression of BID protein [Maneb co-treated with Paraquat] results in increased expression of BID protein |
CTD |
PMID:18266926 |
|
NCBI chr 4:153,439,812...153,465,247
Ensembl chr 4:153,442,218...153,465,203
|
|
G |
Bik |
BCL2-interacting killer |
increases expression multiple interactions |
ISO |
Maneb results in increased expression of BIK mRNA; Maneb results in increased expression of BIK protein [Paraquat co-treated with Maneb] results in increased expression of BIK protein |
CTD |
PMID:18266926 |
|
NCBI chr 7:124,390,924...124,410,449
Ensembl chr 7:124,391,432...124,410,447
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions |
ISO |
[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of BMP2 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 3:126,335,963...126,346,771
Ensembl chr 3:126,335,863...126,346,318
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
multiple interactions |
ISO |
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of BMP4 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of BMP4 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr15:20,776,060...20,791,013
Ensembl chr15:20,776,054...20,822,740
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
increases expression |
ISO |
Maneb results in increased expression of BNIP3 mRNA; Maneb results in increased expression of BNIP3 protein |
CTD |
PMID:18266926 |
|
NCBI chr 1:211,248,098...211,265,282
Ensembl chr 1:211,248,098...211,265,282
|
|
G |
Bnip3l |
BCL2 interacting protein 3 like |
increases expression |
ISO |
Maneb results in increased expression of BNIP3L mRNA |
CTD |
PMID:18266926 |
|
NCBI chr15:43,643,897...43,667,123
Ensembl chr15:43,643,897...43,667,029
|
|
G |
Brf1 |
BRF1, RNA polymerase III transcription initiation factor subunit |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of BRF1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 6:137,762,230...137,808,573
Ensembl chr 6:137,765,122...137,808,303
|
|
G |
Cacna1e |
calcium voltage-gated channel subunit alpha1 E |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of CACNA1E mRNA |
CTD |
PMID:22563483 |
|
NCBI chr13:71,899,445...72,534,992
Ensembl chr13:71,906,702...72,367,980
|
|
G |
Cacybp |
calcyclin binding protein |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of CACYBP mRNA |
CTD |
PMID:18386188 |
|
NCBI chr13:77,948,771...77,959,089
Ensembl chr13:77,948,771...77,959,110
|
|
G |
Calm1 |
calmodulin 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of CALM1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CALM1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CALM1 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 6:124,217,241...124,225,292
Ensembl chr 6:124,217,241...124,225,292
|
|
G |
Calm2 |
calmodulin 2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of CALM2 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 6:11,067,675...11,080,078
Ensembl chr15:65,506,874...65,507,968
|
|
G |
Camp |
cathelicidin antimicrobial peptide |
multiple interactions |
ISO EXP |
[Paraquat co-treated with Maneb] affects the expression of CAMP mRNA [Paraquat co-treated with Maneb] results in decreased expression of CAMP mRNA |
CTD |
PMID:22563483 PMID:27460631 |
|
NCBI chr 8:117,930,557...117,932,371
Ensembl chr 8:117,930,546...117,932,518
|
|
G |
Capn11 |
calpain 11 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of CAPN11 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 9:17,728,845...17,750,357
Ensembl chr 9:17,728,816...17,750,363
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of CASP1 mRNA; [Paraquat co-treated with Maneb] results in increased cleavage of CASP1 protein; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased cleavage of CASP1 protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased cleavage of CASP1 protein]; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CASP1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CASP1 mRNA] |
CTD |
PMID:23963992 PMID:32375810 |
|
NCBI chr 8:2,605,743...2,614,637
Ensembl chr 8:2,604,962...2,614,631
|
|
G |
Casp3 |
caspase 3 |
increases activity |
ISO |
Maneb results in increased activity of CASP3 protein |
CTD |
PMID:22824503 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp7 |
caspase 7 |
increases activity |
ISO |
Maneb results in increased activity of CASP7 protein |
CTD |
PMID:22824503 |
|
NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
|
|
G |
Casp8 |
caspase 8 |
increases activity |
ISO |
Maneb results in increased activity of CASP8 protein |
CTD |
PMID:22824503 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases activity |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of CASP9 mRNA; [Paraquat co-treated with Maneb] results in increased expression of CASP9 protein; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CASP9 mRNA]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CASP9 protein]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CASP9 mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CASP9 protein] Maneb results in increased activity of CASP9 protein |
CTD |
PMID:20964710 PMID:22824503 PMID:23963992 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cat |
catalase |
decreases activity multiple interactions |
ISO EXP |
Maneb results in decreased activity of CAT protein [Maneb co-treated with Paraquat] results in increased expression of CAT mRNA |
CTD |
PMID:26210702 PMID:29859004 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccdc88a |
coiled coil domain containing 88A |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of CCDC88A mRNA |
CTD |
PMID:22563483 |
|
NCBI chr14:113,771,093...113,936,376
Ensembl chr14:113,867,209...113,932,263
|
|
G |
Ccl19 |
C-C motif chemokine ligand 19 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of CCL19 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 5:58,181,025...58,182,969
Ensembl chr 5:58,181,026...58,183,017
|
|
G |
Ccl21 |
C-C motif chemokine ligand 21 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of CCL21 mRNA; [Paraquat co-treated with Maneb] affects the expression of CCL21A mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 5:58,197,678...58,198,782
Ensembl chr 5:58,197,680...58,198,782
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO EXP |
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in increased expression of CCND1 protein [Maneb co-treated with Paraquat] results in decreased expression of CCND1 mRNA |
CTD |
PMID:19883720 PMID:29859004 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Ccnd2 |
cyclin D2 |
multiple interactions |
EXP |
[Maneb co-treated with Paraquat] results in decreased expression of CCND2 mRNA |
CTD |
PMID:29859004 |
|
NCBI chr 4:159,674,885...159,697,207
Ensembl chr 4:159,674,885...159,697,207
|
|
G |
Cd34 |
CD34 molecule |
increases expression |
EXP |
Maneb results in increased expression of CD34 |
CTD |
PMID:25803990 |
|
NCBI chr13:113,691,842...113,711,259
Ensembl chr13:113,691,932...113,711,647
|
|
G |
Cd68 |
Cd68 molecule |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of CD68 mRNA; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CD68 mRNA] |
CTD |
PMID:32169474 |
|
NCBI chr10:56,268,726...56,270,605
Ensembl chr10:56,268,720...56,270,640
|
|
G |
Cdhr4 |
cadherin-related family member 4 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of CDHR4 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 8:116,771,377...116,779,242
|
|
G |
Cdipt |
CDP-diacylglycerol--inositol 3-phosphatidyltransferase |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of CDIPT mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 1:198,409,186...198,413,497
Ensembl chr 1:198,409,360...198,413,497
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of CDK2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of CDK2 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of CDK2 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
|
|
G |
Cdk5r1 |
cyclin-dependent kinase 5 regulatory subunit 1 |
multiple interactions |
ISO |
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of CDK5R1 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr10:67,862,054...67,863,255
Ensembl chr10:67,862,054...67,863,255
|
|
G |
Cdk5rap1 |
CDK5 regulatory subunit associated protein 1 |
multiple interactions |
ISO |
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of CDK5RAP1 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 3:149,835,953...149,870,429
Ensembl chr 3:149,703,848...149,870,413
|
|
G |
Cdk5rap2 |
CDK5 regulatory subunit associated protein 2 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of CDK5RAP2 mRNA; LRRK2 protein mutant form inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CDK5RAP2 mRNA]; SNCA protein inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CDK5RAP2 mRNA] |
CTD |
PMID:23017109 |
|
NCBI chr 5:86,387,238...86,554,108
Ensembl chr 5:86,387,078...86,554,102
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of CDKN1A mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CDKN1A mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
multiple interactions increases expression |
EXP |
[Maneb co-treated with Paraquat] results in increased expression of CDKN2A mRNA Maneb results in increased expression of CDKN2A mRNA |
CTD |
PMID:29859004 |
|
NCBI chr 5:107,823,323...107,832,405
Ensembl chr 5:107,823,330...107,841,175
|
|
G |
Cebpd |
CCAAT/enhancer binding protein delta |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of CEBPD mRNA |
CTD |
PMID:22563483 |
|
NCBI chr11:89,008,008...89,009,146
Ensembl chr11:89,008,008...89,009,146
|
|
G |
Cep290 |
centrosomal protein 290 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of CEP290 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 7:40,217,269...40,306,327
Ensembl chr 7:40,217,269...40,306,327
|
|
G |
Chrm2 |
cholinergic receptor, muscarinic 2 |
multiple interactions |
ISO |
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of CHRM2 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 4:64,089,028...64,091,090
Ensembl chr 4:64,088,900...64,091,090
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased phosphorylation of CHUK protein; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased phosphorylation of CHUK protein] |
CTD |
PMID:29568078 |
|
NCBI chr 1:263,848,829...263,884,354
Ensembl chr 1:263,848,884...263,885,169
|
|
G |
Cirbp |
cold inducible RNA binding protein |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of CIRBP mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 7:12,400,066...12,405,054
Ensembl chr 7:12,401,207...12,405,022
|
|
G |
Clca1 |
chloride channel accessory 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of CLCA1 mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of CLCA1 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 2:250,897,980...250,923,711
Ensembl chr 2:250,897,969...250,923,744
|
|
G |
Clu |
clusterin |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of CLU mRNA |
CTD |
PMID:18386188 |
|
NCBI chr15:42,626,612...42,665,858
Ensembl chr15:42,640,146...42,665,857
|
|
G |
Cope |
COPI coat complex subunit epsilon |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of COPE mRNA |
CTD |
PMID:18386188 |
|
NCBI chr16:20,863,141...20,873,516
Ensembl chr16:20,863,141...20,873,521
|
|
G |
Cox5a |
cytochrome c oxidase subunit 5A |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of COX5A protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of COX5A protein]; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of COX5A protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of COX5A protein] |
CTD |
PMID:23562983 |
|
NCBI chr 8:62,298,358...62,309,765
Ensembl chr 8:62,298,358...62,309,765
|
|
G |
Cox6a1 |
cytochrome c oxidase subunit 6A1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of COX6A1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr12:47,024,442...47,027,495
Ensembl chr12:47,024,442...47,027,495
|
|
G |
Cox6b1 |
cytochrome c oxidase subunit 6B1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of COX6B1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of COX6B1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of COX6B1 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 1:89,075,987...89,084,834
Ensembl chr 1:89,075,975...89,084,859 Ensembl chr 2:89,075,975...89,084,859
|
|
G |
Cox7a2 |
cytochrome c oxidase subunit 7A2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of COX7A2 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 8:87,209,529...87,213,627
Ensembl chr 8:87,209,530...87,213,627
|
|
G |
Cox7a2l |
cytochrome c oxidase subunit 7A2 like |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of COX7A2L mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 6:6,695,807...6,709,790
Ensembl chr 6:6,695,827...6,709,783
|
|
G |
Cplx1 |
complexin 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of CPLX1 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of CPLX1 protein |
CTD |
PMID:17532186 |
|
NCBI chr14:2,194,895...2,226,610
Ensembl chr14:2,194,933...2,226,598
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO EXP |
[Maneb co-treated with Paraquat] results in decreased expression of CREB1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of CREB1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of CREB1 mRNA] [Paraquat co-treated with Maneb] results in decreased expression of CREB1 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of CREB1 protein; [Paraquat co-treated with Maneb] results in decreased expression of CREB1 protein modified form |
CTD |
PMID:23963992 PMID:27460631 |
|
NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
|
|
G |
Crip2 |
cysteine-rich protein 2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of CRIP2 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 6:137,953,545...137,958,491
Ensembl chr 6:137,953,545...137,958,490
|
|
G |
Crlf2 |
cytokine receptor-like factor 2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of CRLF2 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr14:1,456,843...1,461,543
Ensembl chr14:1,456,844...1,461,543
|
|
G |
Crot |
carnitine O-octanoyltransferase |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of CROT mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 4:22,079,837...22,116,265
Ensembl chr 4:22,081,604...22,116,265
|
|
G |
Csf1r |
colony stimulating factor 1 receptor |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of CSF1R mRNA; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CSF1R mRNA] |
CTD |
PMID:32169474 |
|
NCBI chr18:56,414,493...56,458,300
Ensembl chr18:56,414,488...56,458,300
|
|
G |
Csf2ra |
colony stimulating factor 2 receptor subunit alpha |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of CSF2RA mRNA; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CSF2RA mRNA] |
CTD |
PMID:32169474 |
|
NCBI chr14:1,462,292...1,467,264
Ensembl chr14:1,462,358...1,467,264
|
|
G |
Ctsl |
cathepsin L |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of CTSL mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CTSL mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr17:1,873,105...1,879,266
Ensembl chr17:1,872,848...1,879,279
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of NOX2 mRNA; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOX2 mRNA]; diphenyleneiodonium inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOX2 mRNA] [Paraquat co-treated with Maneb] results in increased expression of CYBB protein; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYBB protein]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYBB protein] |
CTD |
PMID:29568078 PMID:30797899 PMID:32375810 |
|
NCBI chr X:14,578,330...14,610,049
Ensembl chr X:14,578,264...14,612,547
|
|
G |
Cyc1 |
cytochrome c-1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of CYC1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 7:117,409,576...117,411,953
Ensembl chr 7:117,409,576...117,411,953
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases activity decreases expression increases expression |
EXP ISO |
Maneb results in increased activity of CYP1A1 protein Maneb results in decreased expression of CYP1A1 mRNA Maneb results in increased expression of CYP1A1 mRNA; Maneb results in increased expression of CYP1A1 protein |
CTD |
PMID:20888808 PMID:32194361 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
[Paraquat co-treated with Maneb] results in increased expression of and results in increased activity of CYP1A2 protein; [Paraquat co-treated with Maneb] results in increased expression of CYP1A2 mRNA; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of and results in increased activity of CYP1A2 protein]; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP1A2 mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of and results in increased activity of CYP1A2 protein]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP1A2 mRNA] |
CTD |
PMID:23159886 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
decreases expression |
ISO |
Maneb results in decreased expression of CYP2C19 protein |
CTD |
PMID:32194361 |
|
NCBI chr 1:147,713,879...147,814,410
Ensembl chr 1:147,713,892...147,888,007
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
multiple interactions decreases expression |
ISO |
Ketoconazole inhibits the reaction [Maneb results in decreased expression of CYP2D22 protein] |
CTD |
PMID:22334051 |
|
NCBI chr 7:123,599,264...123,608,436
Ensembl chr 7:123,599,266...123,608,436
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases activity increases expression multiple interactions increases activity |
EXP ISO |
Maneb results in decreased activity of CYP2E1 protein Maneb results in increased expression of CYP2E1 mRNA; Maneb results in increased expression of CYP2E1 protein [Maneb co-treated with Paraquat] results in increased expression of and results in increased activity of CYP2E1 protein; [Maneb co-treated with Paraquat] results in increased expression of CYP2E1 mRNA; Acetylcysteine inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of and results in increased activity of CYP2E1 protein]; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP2E1 mRNA]; Acetylcysteine inhibits the reaction [Maneb results in increased expression of and results in increased activity of CYP2E1 protein]; Acetylcysteine inhibits the reaction [Maneb results in increased expression of CYP2E1 mRNA]; Maneb results in increased expression of and results in increased activity of CYP2E1 protein; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of and results in increased activity of CYP2E1 protein]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP2E1 mRNA]; Silymarin inhibits the reaction [Maneb results in increased expression of and results in increased activity of CYP2E1 protein]; Silymarin inhibits the reaction [Maneb results in increased expression of CYP2E1 mRNA] Maneb results in increased activity of CYP2E1 protein [Maneb co-treated with Paraquat] results in increased expression of CYP2E1 mRNA; [Paraquat co-treated with Maneb] results in increased activity of CYP2E1 protein; [Paraquat co-treated with Maneb] results in increased expression of CYP2E1 mRNA; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased activity of CYP2E1 protein]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP2E1 mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased activity of CYP2E1 protein]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP2E1 mRNA] |
CTD |
PMID:11043497 PMID:16510128 PMID:20888808 PMID:20964710 PMID:23159886 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
decreases expression |
ISO |
Maneb results in decreased expression of CYP7A1 mRNA |
CTD |
PMID:32194361 |
|
NCBI chr 5:19,358,734...19,368,431
Ensembl chr 5:19,358,734...19,368,431
|
|
G |
Dap3 |
death associated protein 3 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of DAP3 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of DAP3 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 2:188,225,607...188,255,324
Ensembl chr 2:188,225,613...188,252,725
|
|
G |
Dbi |
diazepam binding inhibitor, acyl-CoA binding protein |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of DBI mRNA |
CTD |
PMID:18386188 |
|
NCBI chr13:36,147,667...36,156,076
Ensembl chr13:36,117,119...36,174,908
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
increases expression |
EXP |
Maneb results in increased expression of DDIT4 protein |
CTD |
PMID:24764117 |
|
NCBI chr20:29,509,283...29,511,382
Ensembl chr20:29,509,289...29,511,382
|
|
G |
Ddx5 |
DEAD-box helicase 5 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of DDX5 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr10:94,979,759...94,988,461
Ensembl chr10:94,980,928...94,988,461
|
|
G |
Dgki |
diacylglycerol kinase, iota |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of DGKI mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 4:64,365,115...64,831,473
Ensembl chr 4:64,374,342...64,831,473
|
|
G |
Dio1 |
iodothyronine deiodinase 1 |
decreases activity |
ISO |
Maneb results in decreased activity of DIO1 protein |
CTD |
PMID:29228274 |
|
NCBI chr 5:126,894,837...126,911,532
Ensembl chr 5:126,895,286...126,911,520
|
|
G |
Dip2b |
disco-interacting protein 2 homolog B |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of DIP2B mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 7:141,702,034...141,878,945
Ensembl chr 7:141,702,038...141,879,951
|
|
G |
Dll1 |
delta like canonical Notch ligand 1 |
multiple interactions |
ISO |
[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of DLL1 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 1:57,318,621...57,326,732
Ensembl chr 1:57,318,708...57,327,379
|
|
G |
Dlst |
dihydrolipoamide S-succinyltransferase |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of DLST protein; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of DLST protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of DLST protein] |
CTD |
PMID:23562983 |
|
NCBI chr 6:108,936,534...108,961,322
Ensembl chr 6:108,936,664...108,959,803
|
|
G |
Dmrta2 |
DMRT-like family A2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of DMRTA2 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 5:129,754,295...129,760,045
Ensembl chr 5:129,756,149...129,758,986
|
|
G |
Dnajb6 |
DnaJ heat shock protein family (Hsp40) member B6 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of DNAJB6 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 4:2,711,329...2,774,969
Ensembl chr 4:2,711,385...2,774,890
|
|
G |
Dnm2 |
dynamin 2 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of DNM2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of DNM2 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 8:22,458,869...22,540,649
Ensembl chr 8:22,458,899...22,540,524
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions |
ISO |
[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of DRD2 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 8:53,678,777...53,743,643
Ensembl chr 8:53,678,777...53,743,642
|
|
G |
Drd4 |
dopamine receptor D4 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of DRD4 protein |
CTD |
PMID:22563483 |
|
NCBI chr 1:214,278,296...214,282,818
Ensembl chr 1:214,278,296...214,281,483
|
|
G |
Drd5 |
dopamine receptor D5 |
multiple interactions |
ISO |
[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of DRD5 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr14:77,220,579...77,222,006
Ensembl chr14:77,220,579...77,222,006
|
|
G |
E2f1 |
E2F transcription factor 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of E2F1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of E2F1 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 3:150,062,895...150,073,721
Ensembl chr 3:150,047,826...150,073,721
|
|
G |
Eef1a1 |
eukaryotic translation elongation factor 1 alpha 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of EEF1A1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 8:85,838,594...85,841,816
Ensembl chr 8:85,838,869...85,840,818
|
|
G |
Eef1g |
eukaryotic translation elongation factor 1 gamma |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of EEF1G mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of EEF1G mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of EEF1G mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 1:225,163,391...225,173,997
Ensembl chr 1:225,163,391...225,173,995
|
|
G |
Efnb1 |
ephrin B1 |
multiple interactions |
ISO |
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of EFNB1 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr X:68,891,227...68,904,034
Ensembl chr X:68,891,227...68,904,038
|
|
G |
Egr4 |
early growth response 4 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of EGR4 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 4:117,293,620...117,296,082
Ensembl chr 4:117,293,620...117,296,082
|
|
G |
Eif4g2 |
eukaryotic translation initiation factor 4, gamma 2 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of EIF4G2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of EIF4G2 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 1:175,883,362...175,895,510
Ensembl chr 1:175,883,363...175,895,510
|
|
G |
Elk1 |
ETS transcription factor ELK1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of ELK1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ELK1 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr X:1,287,875...1,304,822
Ensembl chr X:1,297,099...1,304,822
|
|
G |
Eno1 |
enolase 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of ENO1 protein; [Paraquat co-treated with Maneb] results in decreased expression of ENO1 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of ENO1 protein; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of ENO1 protein] |
CTD |
PMID:17532186 PMID:18386188 PMID:23562983 |
|
NCBI chr 5:167,288,223...167,299,610
Ensembl chr 5:167,288,223...167,299,609
|
|
G |
Eno2 |
enolase 2 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of ENO2 protein |
CTD |
PMID:23562983 |
|
NCBI chr 4:157,285,192...157,294,090
Ensembl chr 4:157,285,179...157,294,047
|
|
G |
Etl4 |
enhancer trap locus 4 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of ETL4 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr17:87,173,265...87,681,268
Ensembl chr17:87,274,944...87,681,317
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of FAS mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of FAS mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of FAS mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
|
|
G |
Fez1 |
fasciculation and elongation protein zeta 1 |
multiple interactions |
ISO |
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of FEZ1 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 8:39,305,128...39,350,270
Ensembl chr 8:39,305,128...39,350,270
|
|
G |
Fgfr3 |
fibroblast growth factor receptor 3 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of FGFR3 mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of FGFR3 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr14:82,272,322...82,287,739
Ensembl chr14:82,273,070...82,287,706
|
|
G |
Fkbp4 |
FKBP prolyl isomerase 4 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of FKBP4 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 4:161,748,993...161,757,447
Ensembl chr 4:161,748,993...161,757,447
|
|
G |
Fkbp5 |
FKBP prolyl isomerase 5 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of FKBP5 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr20:7,976,704...8,097,290
Ensembl chr20:7,976,713...8,019,020
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO EXP |
[Maneb co-treated with Paraquat] results in increased expression of FOS mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of FOS mRNA] [Paraquat co-treated with Maneb] results in decreased expression of FOS mRNA; [Paraquat co-treated with Maneb] results in decreased expression of FOS protein |
CTD |
PMID:23963992 PMID:27460631 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Fxyd6 |
FXYD domain-containing ion transport regulator 6 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of FXYD6 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 8:49,676,520...49,703,419
Ensembl chr 8:49,676,540...49,703,419
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
decreases expression |
ISO |
Maneb results in decreased expression of G6PC1 mRNA |
CTD |
PMID:32194361 |
|
NCBI chr10:89,286,009...89,296,213
Ensembl chr10:89,285,855...89,296,213
|
|
G |
Gabra6 |
gamma-aminobutyric acid type A receptor subunit alpha6 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of GABRA6 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr10:27,847,447...27,862,896
Ensembl chr10:27,847,439...27,862,868
|
|
G |
Gas5 |
growth arrest specific 5 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of GAS5 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr13:78,852,523...78,855,844
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression increases activity |
ISO EXP |
[Maneb results in increased expression of NFE2L2 protein] which results in increased expression of GCLC mRNA Maneb results in increased activity of GCLC protein |
CTD |
PMID:15527874 PMID:21402726 |
|
NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of GFAP protein; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of GFAP protein] |
CTD |
PMID:30797899 |
|
NCBI chr10:90,990,762...90,999,435
Ensembl chr10:90,990,762...90,999,506
|
|
G |
Gh1 |
growth hormone 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of GH mRNA |
CTD |
PMID:22563483 |
|
NCBI chr10:94,486,204...94,488,181
Ensembl chr10:94,486,205...94,488,180
|
|
G |
Gm2a |
GM2 ganglioside activator |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of GM2A mRNA |
CTD |
PMID:18386188 |
|
NCBI chr10:40,438,394...40,450,927
Ensembl chr10:40,438,356...40,450,930
|
|
G |
Gmfb |
glia maturation factor, beta |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of GMFB mRNA; [Paraquat co-treated with Maneb] results in decreased expression of GMFB protein |
CTD |
PMID:17532186 |
|
NCBI chr15:23,597,846...23,611,541
Ensembl chr15:23,601,368...23,606,634
|
|
G |
Gng5 |
G protein subunit gamma 5 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of GNG5 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 2:252,359,976...252,368,473
Ensembl chr 2:252,359,976...252,368,473
|
|
G |
Gngt2 |
G protein subunit gamma transducin 2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of GNGT2 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr10:83,654,321...83,658,601
Ensembl chr10:83,655,460...83,658,589
|
|
G |
Gpr27 |
G protein-coupled receptor 27 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of GPR27 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 4:132,137,793...132,138,926
Ensembl chr 4:132,137,793...132,138,926
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions decreases expression |
ISO EXP |
GPX1 protein results in decreased susceptibility to [Paraquat co-treated with Maneb] [Maneb co-treated with Paraquat] results in increased expression of GPX1 mRNA Maneb results in decreased expression of GPX1 mRNA |
CTD |
PMID:15824117 PMID:26210702 PMID:29859004 |
|
NCBI chr 8:117,117,430...117,118,528
Ensembl chr 8:117,117,430...117,118,522
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
increases expression multiple interactions |
ISO |
Maneb results in increased expression of GPX4 mRNA [Paraquat co-treated with Maneb] results in decreased expression of GPX4 protein [Paraquat co-treated with Maneb] results in decreased expression of GPX4 protein; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of GPX4 protein]; NFE2L2 gene mutant form inhibits the reaction [Maneb results in increased expression of GPX4 mRNA] |
CTD |
PMID:23764462 PMID:30797899 |
|
NCBI chr 7:12,516,357...12,519,154
Ensembl chr 7:12,516,352...12,519,154
|
|
G |
Grb2 |
growth factor receptor bound protein 2 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of GRB2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of GRB2 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of GRB2 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr10:104,193,953...104,263,071
Ensembl chr10:104,193,955...104,263,071
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
ISO |
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] affects the phosphorylation of GSK3B protein |
CTD |
PMID:19883720 |
|
NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP ISO |
[Acetylcysteine co-treated with Paraquat co-treated with Maneb] results in increased activity of GSR protein; [Silymarin co-treated with Maneb] results in increased activity of GSR protein; [Silymarin co-treated with Paraquat co-treated with Maneb] results in increased activity of GSR protein [NFE2L2 gene mutant form results in increased susceptibility to Maneb] which results in decreased expression of GSR protein |
CTD |
PMID:23159886 PMID:23764462 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
increases expression |
EXP |
Maneb results in increased expression of GSTA3 mRNA |
CTD |
PMID:20888808 |
|
NCBI chr 8:85,640,081...85,645,621
|
|
G |
Gsta4 |
glutathione S-transferase alpha 4 |
multiple interactions increases activity increases expression |
EXP |
[Paraquat co-treated with Maneb] results in increased expression of and results in increased activity of GSTA4 protein; [Paraquat co-treated with Maneb] results in increased expression of GSTA4 mRNA; Acetylcysteine promotes the reaction [[Paraquat co-treated with Maneb] results in increased expression of and results in increased activity of GSTA4 protein]; Acetylcysteine promotes the reaction [[Paraquat co-treated with Maneb] results in increased expression of GSTA4 mRNA]; Acetylcysteine promotes the reaction [Maneb results in increased expression of and results in increased activity of GSTA4 protein]; Acetylcysteine promotes the reaction [Maneb results in increased expression of GSTA4 mRNA]; Maneb results in increased expression of and results in increased activity of GSTA4 protein; Silymarin promotes the reaction [[Paraquat co-treated with Maneb] results in increased expression of and results in increased activity of GSTA4 protein]; Silymarin promotes the reaction [[Paraquat co-treated with Maneb] results in increased expression of GSTA4 mRNA]; Silymarin promotes the reaction [Maneb results in increased expression of and results in increased activity of GSTA4 protein]; Silymarin promotes the reaction [Maneb results in increased expression of GSTA4 mRNA] Maneb results in increased activity of GSTA4 protein Maneb results in increased expression of GSTA4 mRNA; Maneb results in increased expression of GSTA4 protein |
CTD |
PMID:20888808 PMID:23159886 |
|
NCBI chr 8:85,497,557...85,514,732
Ensembl chr 8:85,497,557...85,518,879
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of GSTP1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of GSTP1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of GSTP1 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
|
|
G |
Guk1 |
guanylate kinase 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of GUK1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr10:45,535,617...45,552,455
Ensembl chr10:45,535,627...45,543,897
|
|
G |
H2ac20 |
H2A clustered histone 20 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of H2AC20 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 2:198,360,271...198,360,735
Ensembl chr 2:198,360,301...198,360,678
|
|
G |
H2bu1 |
H2B.U histone 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of H2BC9 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr10:45,296,638...45,297,385
Ensembl chr10:45,296,638...45,297,385
|
|
G |
Hba-a1 |
hemoglobin alpha, adult chain 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of HBA-A1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr10:15,602,794...15,603,649
Ensembl chr10:15,602,794...15,603,649
|
|
G |
Hdac3 |
histone deacetylase 3 |
decreases activity |
ISO |
Maneb results in decreased activity of HDAC3 protein |
CTD |
PMID:21251949 |
|
NCBI chr18:31,073,057...31,094,347
Ensembl chr18:31,073,058...31,094,303
|
|
G |
Hdac6 |
histone deacetylase 6 |
decreases activity |
ISO |
Maneb results in decreased activity of HDAC6 protein |
CTD |
PMID:21251949 |
|
NCBI chr X:15,295,372...15,316,673
Ensembl chr X:15,295,473...15,316,671
|
|
G |
Hes3 |
hes family bHLH transcription factor 3 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of HES3 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 5:169,463,196...169,469,795
Ensembl chr 5:169,464,989...169,467,153
|
|
G |
Hey2 |
hes-related family bHLH transcription factor with YRPW motif 2 |
multiple interactions |
ISO |
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of HEY2 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 1:29,191,170...29,201,257
Ensembl chr 1:29,191,192...29,201,531
|
|
G |
Heyl |
hes-related family bHLH transcription factor with YRPW motif-like |
multiple interactions |
ISO |
[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of HEYL mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 5:140,923,914...140,940,905
Ensembl chr 5:140,923,914...140,940,905
|
|
G |
Hist3h2a |
histone cluster 3, H2a |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of H2AC6 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr10:45,297,603...45,299,155
|
|
G |
Hk1 |
hexokinase 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of HK1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr20:31,911,460...31,979,780
Ensembl chr20:31,912,262...31,956,649
|
|
G |
Hmga2 |
high mobility group AT-hook 2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of HMGA2 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 7:65,159,944...65,275,408
Ensembl chr 7:65,159,944...65,275,408
|
|
G |
Hmgn5 |
high mobility group nucleosome binding domain 5 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of HMGN5 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr X:80,134,557...80,142,902
Ensembl chr X:80,134,557...80,142,902
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
EXP ISO |
Maneb results in increased expression of HMOX1 protein [NFE2L2 gene mutant form results in increased susceptibility to Maneb] which results in decreased expression of HMOX1 protein |
CTD |
PMID:15527874 PMID:23764462 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hnrnpk |
heterogeneous nuclear ribonucleoprotein K |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of HNRNPK mRNA |
CTD |
PMID:18386188 |
|
NCBI chr17:6,664,730...6,676,753
Ensembl chr17:6,665,659...6,676,654
|
|
G |
Hsd11b2 |
hydroxysteroid 11-beta dehydrogenase 2 |
decreases activity |
ISO |
Maneb results in decreased activity of HSD11B2 protein |
CTD |
PMID:22796344 |
|
NCBI chr19:37,476,083...37,481,326
Ensembl chr19:37,476,095...37,481,307
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of HSF1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of HSF1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of HSF1 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 7:117,538,523...117,565,478
Ensembl chr 7:117,538,523...117,565,478
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of HSP90AA1 mRNA; [Paraquat co-treated with Maneb] results in increased expression of HSP90AA1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of HSP90AA1 mRNA] |
CTD |
PMID:18386188 PMID:23963992 |
|
NCBI chr 6:135,107,262...135,112,793
Ensembl chr 6:135,107,271...135,112,775
|
|
G |
Hspa1b |
heat shock protein family A (Hsp70) member 1B |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of HSPA1B mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of HSPA1B mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr20:4,877,638...4,880,112
Ensembl chr20:2,699,712...2,701,815
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of HSPA5 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of HSPA8 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 8:44,989,401...44,993,261
Ensembl chr 8:44,990,014...44,993,179
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of ICAM1 mRNA; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of ICAM1 mRNA] |
CTD |
PMID:32169474 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Icam2 |
intercellular adhesion molecule 2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of ICAM2 mRNA; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of ICAM2 mRNA] |
CTD |
PMID:32169474 |
|
NCBI chr10:94,569,889...94,581,218
Ensembl chr10:94,569,890...94,576,512
|
|
G |
Idh3a |
isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of IDH3A protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IDH3A protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IDH3A protein] |
CTD |
PMID:23562983 |
|
NCBI chr 8:59,164,601...59,183,899
Ensembl chr 8:59,164,572...59,183,908
|
|
G |
Ier5l |
immediate early response 5-like |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of IER5L mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 3:9,036,351...9,037,942
Ensembl chr 3:9,036,373...9,037,942
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of IFNG mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IFNG mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IFNG mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of IGF1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of IGF1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of IGF1 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 7:28,412,123...28,491,815
Ensembl chr 7:28,412,198...28,486,609
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression |
EXP ISO |
[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA]; Silymarin inhibits the reaction [Maneb results in increased expression of IL1B mRNA] [Maneb co-treated with Paraquat] results in increased expression of IL1B mRNA; [Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA; [Paraquat co-treated with Maneb] results in increased expression of IL1B protein; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B protein]; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IL1B mRNA]; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IL1B mRNA]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA] |
CTD |
PMID:23159886 PMID:23963992 PMID:29568078 PMID:32169474 PMID:32375810 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of IL6 mRNA; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL6 mRNA] |
CTD |
PMID:32169474 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Inhba |
inhibin subunit beta A |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of INHBA mRNA; [Paraquat co-treated with Maneb] affects the expression of INHBA mRNA |
CTD |
PMID:22563483 PMID:23017109 |
|
NCBI chr17:51,894,869...51,919,998
Ensembl chr17:51,898,217...51,912,496
|
|
G |
Irs2 |
insulin receptor substrate 2 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of IRS2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of IRS2 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr16:83,824,515...83,848,569
Ensembl chr16:83,824,430...83,848,684
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of ITGAM protein; [Paraquat co-treated with Maneb] results in increased expression of ITGAM mRNA; [Paraquat co-treated with Maneb] results in increased expression of ITGAM protein; acetovanillone inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of ITGAM protein]; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of ITGAM protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased cleavage of CASP1 protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of NLRP3 protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA]; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of ITGAM mRNA] |
CTD |
PMID:28202386 PMID:30797899 PMID:32169474 PMID:32375810 |
|
NCBI chr 1:199,495,312...199,545,738
Ensembl chr 1:199,495,298...199,623,960
|
|
G |
Itgb8 |
integrin subunit beta 8 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of ITGB8 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 6:147,089,280...147,172,846
Ensembl chr 6:147,094,097...147,172,813
|
|
G |
Itpr1 |
inositol 1,4,5-trisphosphate receptor, type 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of ITPR1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ITPR1 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 4:140,247,297...140,580,749
Ensembl chr 4:140,247,313...140,580,748
|
|
G |
Jpt1 |
Jupiter microtubule associated homolog 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of JPT1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr10:104,057,739...104,075,776
Ensembl chr10:104,057,697...104,075,777
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
[Paraquat co-treated with Maneb] results in decreased expression of JUN mRNA; [Paraquat co-treated with Maneb] results in decreased expression of JUN protein |
CTD |
PMID:27460631 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Kcna2 |
potassium voltage-gated channel subfamily A member 2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of KCNA2 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 2:209,838,607...209,852,471
Ensembl chr 2:209,838,869...209,852,471
|
|
G |
Kcnma1 |
potassium calcium-activated channel subfamily M alpha 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of KCNMA1 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr15:344,204...1,048,849
Ensembl chr15:344,360...1,047,956
|
|
G |
Kif1b |
kinesin family member 1B |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of KIF1B mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 5:165,994,803...166,133,497
Ensembl chr 5:165,938,576...166,133,491
|
|
G |
Kit |
KIT proto-oncogene receptor tyrosine kinase |
decreases expression |
EXP |
Maneb results in decreased expression of KIT |
CTD |
PMID:25803990 |
|
NCBI chr14:35,072,131...35,149,638
Ensembl chr14:35,072,108...35,149,610
|
|
G |
Klf2 |
Kruppel-like factor 2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of KLF2 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr16:19,223,087...19,225,037
Ensembl chr16:19,223,087...19,225,037
|
|
G |
Klhl15 |
kelch-like family member 15 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of KLHL15 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr X:63,342,277...63,390,915
Ensembl chr X:63,343,546...63,389,989
|
|
G |
Lamc2 |
laminin subunit gamma 2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of LAMC2 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr13:70,566,643...70,632,126
Ensembl chr13:70,566,643...70,626,252
|
|
G |
Lifr |
LIF receptor subunit alpha |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of LIFR mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 2:56,424,910...56,489,346
Ensembl chr 2:56,426,367...56,489,415
|
|
G |
Limk2 |
LIM domain kinase 2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of LIMK2 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr14:83,564,048...83,641,996
Ensembl chr14:83,573,928...83,641,892
|
|
G |
Loricrin |
loricrin cornified envelope precursor protein |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of LOR mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 2:191,984,455...191,990,713
Ensembl chr 2:191,984,773...191,986,170
|
|
G |
Lrp4 |
LDL receptor related protein 4 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of LRP4 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 3:80,362,643...80,416,684
Ensembl chr 3:80,362,858...80,416,679
|
|
G |
Lrrc17 |
leucine rich repeat containing 17 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of LRRC17 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 4:10,108,184...10,138,652
Ensembl chr 4:10,108,192...10,138,652
|
|
G |
Lrrc41 |
leucine rich repeat containing 41 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of LRRC41 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 5:134,927,609...134,948,530
Ensembl chr 5:134,927,609...134,948,529
|
|
G |
Lrrk2 |
leucine-rich repeat kinase 2 |
multiple interactions |
ISO |
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of ACHE mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of BMP4 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of CDK5R1 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of CDK5RAP1 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of CHRM2 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of EFNB1 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of FEZ1 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of HEY2 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of NDP mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of NRG1 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of NTN1 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of PAX6 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of POU3F3 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of VEGFA mRNA; LRRK2 protein mutant form inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CDK5RAP2 mRNA] |
CTD |
PMID:23017109 |
|
NCBI chr 7:132,857,311...133,018,549
Ensembl chr 7:132,857,628...133,018,584
|
|
G |
Lynx1 |
Ly6/neurotoxin 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of LYNX1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 7:115,982,877...115,988,121
Ensembl chr 7:115,982,876...115,988,090
|
|
G |
Macf1 |
microtubule-actin crosslinking factor 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of MACF1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 5:141,039,455...141,363,524
Ensembl chr 5:141,039,468...141,363,524
|
|
G |
Map2 |
microtubule-associated protein 2 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of MAP2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAP2 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAP2 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 9:73,204,753...73,462,965
Ensembl chr 9:73,319,710...73,462,972
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of MAP2K1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAP2K1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAP2K1 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 8:69,134,218...69,722,573
Ensembl chr 8:69,134,223...69,164,758
|
|
G |
Map2k6 |
mitogen-activated protein kinase kinase 6 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of MAP2K6 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of MAP2K6 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of MAP2K6 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr10:98,707,160...98,823,054
Ensembl chr10:98,706,960...98,823,287
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased phosphorylation of MAPK1 protein [Paraquat co-treated with Maneb] results in increased phosphorylation of MAPK1 protein; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:15824117 PMID:30797899 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk15 |
mitogen-activated protein kinase 15 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of MAPK15 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 7:117,041,287...117,061,799
Ensembl chr 7:117,055,395...117,061,047
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased phosphorylation of MAPK3 protein [Paraquat co-treated with Maneb] results in increased phosphorylation of MAPK3 protein; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:15824117 PMID:30797899 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of MAPT mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAPT mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAPT mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr10:92,289,002...92,386,517
Ensembl chr10:92,288,910...92,386,517
|
|
G |
Marchf9 |
membrane associated ring-CH-type finger 9 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of MARCHF9 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 7:70,341,989...70,349,126
|
|
G |
Mbd3 |
methyl-CpG binding domain protein 3 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of MBD3 mRNA; [Paraquat co-treated with Maneb] results in increased expression of MBD3 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 7:12,179,046...12,186,251
Ensembl chr 7:12,179,203...12,186,656
|
|
G |
Mbnl1 |
muscleblind-like splicing regulator 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of MBNL1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 2:150,698,248...150,867,791
Ensembl chr 2:150,756,185...150,869,690
|
|
G |
Mboat2 |
membrane bound O-acyltransferase domain containing 2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of MBOAT2 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 6:44,009,872...44,135,501
Ensembl chr 6:44,009,872...44,131,387
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
increases expression multiple interactions |
ISO |
Maneb results in increased expression of MCL1 protein [Paraquat co-treated with Maneb] results in increased expression of MCL1 protein |
CTD |
PMID:18266926 |
|
NCBI chr 2:197,786,212...197,788,992
|
|
G |
Mdm4 |
MDM4 regulator of p53 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of MDM4 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr13:49,786,776...49,828,780
Ensembl chr13:49,792,794...49,828,720
|
|
G |
Mef2c |
myocyte enhancer factor 2C |
multiple interactions |
ISO |
[Maneb promotes the reaction [SNCA gene mutant form results in increased susceptibility to Paraquat]] which results in increased metabolism of MEF2C protein; [Paraquat promotes the reaction [SNCA gene mutant form results in increased susceptibility to Maneb]] which results in increased metabolism of MEF2C protein |
CTD |
PMID:24290359 |
|
NCBI chr 2:11,658,534...11,822,788
Ensembl chr 2:11,658,568...11,822,787
|
|
G |
Mfge8 |
milk fat globule EGF and factor V/VIII domain containing |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of MFGE8 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 1:140,845,478...140,860,882
Ensembl chr 1:140,845,465...140,860,894
|
|
G |
Mrc1 |
mannose receptor, C type 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of MRC1 mRNA |
CTD |
PMID:29568078 |
|
NCBI chr17:81,352,700...81,433,743
Ensembl chr17:81,352,700...81,433,743
|
|
G |
Mrpl15 |
mitochondrial ribosomal protein L15 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of MRPL15 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 5:14,609,656...14,620,965
Ensembl chr 5:14,609,674...14,620,965
|
|
G |
Mrtfb |
myocardin related transcription factor B |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of MRTFB mRNA |
CTD |
PMID:22563483 |
|
NCBI chr10:1,151,163...1,273,269
|
|
G |
Mt1 |
metallothionein 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of MT1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr19:11,301,991...11,303,007
Ensembl chr17:78,793,336...78,793,724
|
|
G |
Mthfr |
methylenetetrahydrofolate reductase |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of MTHFR mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 5:164,844,642...164,864,360
Ensembl chr 5:164,845,925...164,860,910
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions increases expression |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of MTOR protein; Maneb promotes the reaction [Paraquat results in increased expression of MTOR protein]; Paraquat promotes the reaction [Maneb results in increased expression of MTOR protein] |
CTD |
PMID:22292029 PMID:26884967 |
|
NCBI chr 5:165,263,813...165,373,967
Ensembl chr 5:165,263,800...165,373,967
|
|
G |
Muc6 |
mucin 6, oligomeric mucus/gel-forming |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of MUC6 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 1:214,608,453...214,630,524
Ensembl chr 1:214,608,704...214,629,938
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
ISO |
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in increased expression of MYC protein |
CTD |
PMID:19883720 |
|
NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] affects the localization of NCF1 protein; [Paraquat co-treated with Maneb] results in increased expression of NCF1 protein; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NCF1 protein]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] affects the localization of NCF1 protein]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NCF1 protein] |
CTD |
PMID:28202386 PMID:29568078 PMID:32375810 |
|
NCBI chr12:25,497,104...25,506,300
Ensembl chr12:25,497,104...25,506,300
|
|
G |
Ndp |
norrin cystine knot growth factor NDP |
multiple interactions |
ISO |
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of NDP mRNA |
CTD |
PMID:23017109 |
|
NCBI chr X:6,791,090...6,815,586
Ensembl chr X:6,791,136...6,815,583 Ensembl chr X:6,791,136...6,815,583
|
|
G |
Neurod1 |
neuronal differentiation 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of NEUROD1 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 3:66,414,314...66,417,617
Ensembl chr 3:66,414,308...66,417,741
|
|
G |
Nfat5 |
nuclear factor of activated T-cells 5 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of NFAT5 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr19:38,446,059...38,533,735
Ensembl chr19:38,446,059...38,533,735
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
increases expression increases response to substance multiple interactions |
ISO |
[Maneb results in increased expression of NFE2L2 protein] which results in increased expression of GCLC mRNA; [Maneb results in increased expression of NFE2L2 protein] which results in increased expression of NQO1 mRNA; [Maneb results in increased expression of NFE2L2 protein] which results in increased expression of PRDX1 mRNA; [Maneb results in increased expression of NFE2L2 protein] which results in increased expression of TXN1 mRNA; [Maneb results in increased expression of NFE2L2 protein] which results in increased expression of TXNRD1 mRNA; Maneb results in increased expression of NFE2L2 protein NFE2L2 gene mutant form results in increased susceptibility to Maneb [NFE2L2 gene mutant form results in increased susceptibility to Maneb] which results in decreased abundance of Glutathione; [NFE2L2 gene mutant form results in increased susceptibility to Maneb] which results in decreased expression of GSR protein; [NFE2L2 gene mutant form results in increased susceptibility to Maneb] which results in decreased expression of HMOX1 protein; [NFE2L2 gene mutant form results in increased susceptibility to Maneb] which results in increased abundance of Manganese; [NFE2L2 gene mutant form results in increased susceptibility to Maneb] which results in increased abundance of Thiobarbituric Acid Reactive Substances; NFE2L2 gene mutant form inhibits the reaction [Maneb results in increased expression of GPX4 mRNA] |
CTD |
PMID:21402726 PMID:23764462 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nfib |
nuclear factor I/B |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of NFIB mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 5:100,436,343...100,647,962
Ensembl chr 5:100,439,082...100,647,727
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of NFKB1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NFKB1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NFKB1 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased phosphorylation of and results in decreased expression of NFKBIA protein; [Paraquat co-treated with Maneb] results in increased degradation of and results in increased phosphorylation of NFKBIA protein; acetovanillone inhibits the reaction [[Maneb co-treated with Paraquat] results in increased phosphorylation of and results in decreased expression of NFKBIA protein]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased degradation of and results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:28202386 PMID:29568078 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Nipbl |
NIPBL, cohesin loading factor |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of NIPBL mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 2:57,508,830...57,676,197
Ensembl chr 2:57,509,428...57,600,820
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of NLRP3 protein; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NLRP3 protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of NLRP3 protein] |
CTD |
PMID:32375810 |
|
NCBI chr10:45,884,324...45,918,290
Ensembl chr10:45,893,018...45,918,254
|
|
G |
Nog |
noggin |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of NOG mRNA |
CTD |
PMID:23017109 |
|
NCBI chr10:76,811,759...76,813,386
Ensembl chr10:76,811,759...76,813,386
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases expression |
ISO EXP |
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; [Maneb co-treated with Paraquat] results in increased expression of NOS2 mRNA; [Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA; [Paraquat co-treated with Maneb] results in increased expression of NOS2 protein; acetovanillone inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NOS2 mRNA]; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; Genistein inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 protein]; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NOS2 mRNA]; pimagedine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; prolinedithiocarbamate inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NOS2 mRNA]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA] [Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; Silymarin inhibits the reaction [Maneb results in increased expression of NOS2 mRNA] |
CTD |
PMID:20455021 PMID:23159886 PMID:23963992 PMID:28202386 PMID:29568078 PMID:30797899 PMID:32375810 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nox1 |
NADPH oxidase 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of NOX1 mRNA; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOX1 mRNA]; diphenyleneiodonium inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOX1 mRNA] |
CTD |
PMID:30797899 |
|
NCBI chr X:104,909,328...104,932,508
Ensembl chr X:104,909,326...104,932,508
|
|
G |
Nps |
neuropeptide S |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of NPS mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 1:207,508,414...207,512,195
Ensembl chr 1:207,508,414...207,512,195
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression |
ISO |
[Maneb results in increased expression of NFE2L2 protein] which results in increased expression of NQO1 mRNA |
CTD |
PMID:21402726 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of NR4A1 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 7:142,899,358...142,920,216
Ensembl chr 7:142,905,758...142,920,216
|
|
G |
Nr4a2 |
nuclear receptor subfamily 4, group A, member 2 |
multiple interactions |
EXP |
[Paraquat co-treated with Maneb] results in decreased expression of NR4A2 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of NR4A2 protein |
CTD |
PMID:29152652 |
|
NCBI chr 3:43,111,258...43,128,391
Ensembl chr 3:43,111,240...43,119,159
|
|
G |
Nrg1 |
neuregulin 1 |
multiple interactions |
ISO |
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of NRG1 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr16:62,969,573...64,065,063
Ensembl chr16:63,837,216...64,057,434
|
|
G |
Nrtn |
neurturin |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of NRTN mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 9:10,299,881...10,306,599
Ensembl chr 9:10,305,470...10,306,597
|
|
G |
Ntn1 |
netrin 1 |
multiple interactions |
ISO |
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of NTN1 mRNA; [Maneb co-treated with Paraquat] results in decreased expression of NTN1 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr10:54,761,925...54,982,072
Ensembl chr10:54,761,871...54,967,585
|
|
G |
Ntrk2 |
neurotrophic receptor tyrosine kinase 2 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of NTRK2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of NTRK2 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of NTRK2 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr17:5,934,651...6,245,778
Ensembl chr17:5,933,729...6,244,676
|
|
G |
Oaz2 |
ornithine decarboxylase antizyme 2 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of OAZ2 mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of OAZ2 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 8:71,216,011...71,229,788
Ensembl chr 8:71,216,178...71,228,713
|
|
G |
P2ry4 |
pyrimidinergic receptor P2Y4 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of P2RY4 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of P2RY4 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr X:70,421,599...70,447,109
Ensembl chr X:70,426,951...70,428,364
|
|
G |
Pax5 |
paired box 5 |
multiple interactions |
ISO |
[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of PAX5 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 5:60,007,587...60,191,973
Ensembl chr 5:60,007,587...60,191,941
|
|
G |
Pax6 |
paired box 6 |
multiple interactions |
ISO |
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of PAX6 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 3:95,700,241...95,728,682
Ensembl chr 3:95,707,386...95,728,624
|
|
G |
Pcdh7 |
protocadherin 7 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of PCDH7 mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of PCDH7 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr14:54,649,054...55,081,632
Ensembl chr14:55,072,200...55,081,551
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
ISO |
3-bromo-7-nitroindazole inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of PCNA protein]; [Paraquat co-treated with Maneb] results in decreased expression of PCNA protein |
CTD |
PMID:23985028 |
|
NCBI chr 3:124,880,698...124,884,570
Ensembl chr 3:124,880,698...124,884,570
|
|
G |
Pcp2 |
Purkinje cell protein 2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of PCP2 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr12:2,172,378...2,174,674
Ensembl chr12:2,172,378...2,174,131
|
|
G |
Pdcd10 |
programmed cell death 10 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of PDCD10 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 2:173,966,701...174,012,730
Ensembl chr 2:173,967,080...174,012,676
|
|
G |
Pde1b |
phosphodiesterase 1B |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of PDE1B mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PDE1B mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 7:145,117,951...145,147,711
Ensembl chr 7:145,117,951...145,145,376
|
|
G |
Pdgfra |
platelet derived growth factor receptor alpha |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of PDGFRA mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of PDGFRA mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr14:35,527,926...35,581,130
Ensembl chr14:35,527,927...35,581,031
|
|
G |
Pdha1 |
pyruvate dehydrogenase E1 subunit alpha 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of PDHA1 mRNA; [Maneb co-treated with Paraquat] results in increased expression of PDHA1 protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of PDHA1 protein]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PDHA1 mRNA] |
CTD |
PMID:23562983 PMID:23963992 |
|
NCBI chr X:37,329,779...37,343,410
Ensembl chr X:37,329,779...37,343,410
|
|
G |
Pdyn |
prodynorphin |
multiple interactions |
EXP |
[Paraquat co-treated with Maneb] results in decreased expression of PDYN |
CTD |
PMID:24376148 |
|
NCBI chr 3:122,194,327...122,206,671
Ensembl chr 3:122,194,329...122,206,671
|
|
G |
Pebp1 |
phosphatidylethanolamine binding protein 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of PEBP1 protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PEBP1 protein] |
CTD |
PMID:23562983 |
|
NCBI chr12:45,026,948...45,031,148
Ensembl chr12:45,026,886...45,031,145
|
|
G |
Pgs1 |
phosphatidylglycerophosphate synthase 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of PGS1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr10:106,994,595...107,030,208
Ensembl chr10:106,991,935...107,030,260
|
|
G |
Pigc |
phosphatidylinositol glycan anchor biosynthesis, class C |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of PIGC mRNA |
CTD |
PMID:18386188 |
|
NCBI chr13:79,886,832...79,889,305
Ensembl chr13:79,886,832...79,889,304
|
|
G |
Plce1 |
phospholipase C, epsilon 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of PLCE1 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 1:257,156,023...257,465,440
Ensembl chr 1:257,157,264...257,466,064
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
increases expression |
ISO |
Maneb results in increased expression of PMAIP1 mRNA; Maneb results in increased expression of PMAIP1 protein |
CTD |
PMID:18266926 |
|
NCBI chr18:62,159,128...62,179,635
Ensembl chr18:62,174,670...62,181,102
|
|
G |
Pnoc |
prepronociceptin |
multiple interactions |
EXP |
[Paraquat co-treated with Maneb] results in increased expression of PNOC |
CTD |
PMID:24376148 |
|
NCBI chr15:48,805,841...48,833,071
Ensembl chr15:48,805,228...48,833,285
|
|
G |
Polr1c |
RNA polymerase I and III subunit C |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of POLR1C mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 9:17,120,759...17,124,871
Ensembl chr 9:17,120,759...17,124,871
|
|
G |
Polr2k |
RNA polymerase II, I and III subunit K |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of POLR2K mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 7:74,939,010...74,992,594
Ensembl chr 7:74,989,223...74,992,582
|
|
G |
Pou3f3 |
POU class 3 homeobox 3 |
multiple interactions |
ISO |
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of POU3F3 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 9:49,479,148...49,482,246
Ensembl chr 9:49,479,023...49,482,252
|
|
G |
Prdx1 |
peroxiredoxin 1 |
increases expression |
ISO |
[Maneb results in increased expression of NFE2L2 protein] which results in increased expression of PRDX1 mRNA |
CTD |
PMID:21402726 |
|
NCBI chr 5:135,536,413...135,551,986
Ensembl chr 5:135,536,413...135,551,990
|
|
G |
Prdx3 |
peroxiredoxin 3 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of PRDX3 protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PRDX3 protein]; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PRDX3 protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PRDX3 protein] |
CTD |
PMID:23562983 |
|
NCBI chr 1:282,238,774...282,251,193
Ensembl chr 1:282,238,773...282,251,257
|
|
G |
Prkaca |
protein kinase cAMP-activated catalytic subunit alpha |
multiple interactions |
EXP |
[Paraquat co-treated with Maneb] results in decreased expression of PRKACA mRNA; [Paraquat co-treated with Maneb] results in decreased expression of PRKACA protein |
CTD |
PMID:27460631 |
|
NCBI chr19:25,095,089...25,118,869
Ensembl chr19:25,095,089...25,118,860
|
|
G |
Prkcz |
protein kinase C, zeta |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of PRKCZ mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 5:172,658,071...172,769,492
Ensembl chr 5:172,658,748...172,769,421
|
|
G |
Prkn |
parkin RBR E3 ubiquitin protein ligase |
multiple interactions |
ISO |
3-bromo-7-nitroindazole inhibits the reaction [[Paraquat co-treated with Maneb] results in increased nitrosation of PRKN protein]; [Paraquat co-treated with Maneb] results in increased expression of PRKN protein; [Paraquat co-treated with Maneb] results in increased nitrosation of PRKN protein |
CTD |
PMID:22563483 PMID:23985028 |
|
NCBI chr 1:48,880,015...50,069,998
|
|
G |
Prl |
prolactin |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of PRL mRNA |
CTD |
PMID:22563483 |
|
NCBI chr17:39,814,236...39,824,299
Ensembl chr17:39,814,244...39,824,299
|
|
G |
Prr7 |
proline rich 7 (synaptic) |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of PRR7 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr17:9,693,274...9,702,795
Ensembl chr17:9,694,168...9,695,292
|
|
G |
Psap |
prosaposin |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of PSAP mRNA |
CTD |
PMID:18386188 |
|
NCBI chr20:29,831,302...29,856,876
Ensembl chr20:29,831,314...29,856,875
|
|
G |
Psen1 |
presenilin 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of PSEN1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of PSEN1 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 6:107,169,514...107,221,000
Ensembl chr 6:107,169,528...107,216,798
|
|
G |
Psmb1 |
proteasome 20S subunit beta 1 |
multiple interactions |
ISO |
Maneb inhibits the reaction [Paraquat results in decreased expression of PSMB1 mRNA] |
CTD |
PMID:26498265 |
|
NCBI chr 1:57,470,878...57,491,359
Ensembl chr 1:57,470,632...57,489,727
|
|
G |
Psmc4 |
proteasome 26S subunit, ATPase 4 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of PSMC4 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PSMC4 mRNA] [Paraquat co-treated with Maneb] results in decreased expression of PSMC4 mRNA |
CTD |
PMID:23963992 PMID:26498265 |
|
NCBI chr 1:84,978,220...84,986,536
Ensembl chr 1:84,978,206...84,986,581
|
|
G |
Ptk2b |
protein tyrosine kinase 2 beta |
multiple interactions |
ISO |
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in decreased expression of PTK2B protein modified form |
CTD |
PMID:19883720 |
|
NCBI chr15:42,827,306...42,947,796
Ensembl chr15:42,827,310...42,947,656
|
|
G |
Ptpn4 |
protein tyrosine phosphatase, non-receptor type 4 |
affects activity |
ISO |
Maneb affects the activity of PTPN4 protein |
CTD |
PMID:23611293 |
|
NCBI chr13:35,678,240...35,858,414
Ensembl chr13:35,678,240...35,858,390
|
|
G |
Ptpn9 |
protein tyrosine phosphatase, non-receptor type 9 |
affects activity |
ISO |
Maneb affects the activity of PTPN9 protein |
CTD |
PMID:23611293 |
|
NCBI chr 8:61,658,851...61,739,458
Ensembl chr 8:61,659,445...61,739,434
|
|
G |
Raf1 |
Raf-1 proto-oncogene, serine/threonine kinase |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of RAF1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of RAF1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of RAF1 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 4:147,532,040...147,592,769
Ensembl chr 4:147,532,042...147,592,699
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions increases expression |
EXP |
[Maneb co-treated with Paraquat] results in increased expression of RB1 mRNA; Acetylcysteine inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of RB1 mRNA]; Acetylcysteine inhibits the reaction [Maneb results in increased expression of RB1 mRNA] |
CTD |
PMID:29859004 |
|
NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
|
|
G |
Rbx1 |
ring-box 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of RBX1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 7:122,700,849...122,710,907
Ensembl chr 7:122,700,854...122,709,935
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased phosphorylation of RELA protein; [Paraquat co-treated with Maneb] results in increased phosphorylation of RELA protein; acetovanillone inhibits the reaction [[Maneb co-treated with Paraquat] results in increased phosphorylation of RELA protein]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased phosphorylation of RELA protein] |
CTD |
PMID:28202386 PMID:29568078 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Ripk1 |
receptor interacting serine/threonine kinase 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of RIPK1 mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of RIPK1 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr17:31,537,580...31,569,904
Ensembl chr17:31,537,591...31,569,904
|
|
G |
Rock1 |
Rho-associated coiled-coil containing protein kinase 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of ROCK1 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr18:1,273,490...1,390,790
Ensembl chr18:1,273,453...1,390,190
|
|
G |
Rpl12 |
ribosomal protein L12 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of RPL12 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 3:12,009,578...12,011,952
Ensembl chr 3:12,009,578...12,011,666
|
|
G |
Rpl19 |
ribosomal protein L19 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of RPL19 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of RPL19 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr10:85,978,691...85,981,979
Ensembl chr10:85,978,691...85,981,979
|
|
G |
Rpl41 |
ribosomal protein L41 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of RPL41 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 7:2,972,897...2,973,977
Ensembl chr 7:2,972,900...2,973,977
|
|
G |
Rpl8 |
ribosomal protein L8 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of RPL8 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 7:117,967,608...117,969,886
Ensembl chr 7:118,507,224...118,509,256
|
|
G |
Rpl9 |
ribosomal protein L9 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of RPL9 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr14:44,524,419...44,527,613
Ensembl chr14:44,524,416...44,527,613
|
|
G |
Rps12 |
ribosomal protein S12 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of RPS12 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 1:22,758,214...22,760,370
Ensembl chr 1:22,758,212...22,760,370
|
|
G |
Rps15 |
ribosomal protein S15 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of RPS15 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 7:12,282,134...12,283,573
Ensembl chr 7:12,282,109...12,283,608
|
|
G |
Rps6ka2 |
ribosomal protein S6 kinase A2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of RPS6KA2 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 1:53,219,346...53,499,445
Ensembl chr 1:53,360,157...53,499,445
|
|
G |
Rtn4 |
reticulon 4 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of RTN4 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr14:114,126,931...114,174,459
Ensembl chr14:114,126,943...114,174,458
|
|
G |
Rtn4rl2 |
reticulon 4 receptor-like 2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of RTN4RL2 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 3:72,272,814...72,289,310
Ensembl chr 3:72,273,424...72,289,310
|
|
G |
S100a8 |
S100 calcium binding protein A8 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of S100A8 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 2:190,073,239...190,074,333
Ensembl chr 2:190,073,815...190,074,354
|
|
G |
S100a9 |
S100 calcium binding protein A9 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of S100A9 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 2:190,097,436...190,100,209
Ensembl chr 2:190,097,554...190,100,276
|
|
G |
Scamp2 |
secretory carrier membrane protein 2 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of SCAMP2 mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of SCAMP2 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 8:62,341,584...62,368,215
Ensembl chr 8:62,341,613...62,368,214
|
|
G |
Scand1 |
SCAN domain-containing 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of SCAND1 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 3:152,381,665...152,382,529
Ensembl chr 3:152,381,665...152,382,529
|
|
G |
Sdhb |
succinate dehydrogenase complex iron sulfur subunit B |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of SDHB mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 5:159,484,378...159,505,063
Ensembl chr 5:159,484,370...159,505,064
|
|
G |
Sema4d |
semaphorin 4D |
multiple interactions |
ISO |
[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of SEMA4D mRNA |
CTD |
PMID:23017109 |
|
NCBI chr17:13,516,276...13,538,513
Ensembl chr17:13,488,376...13,553,974
|
|
G |
Sirt1 |
sirtuin 1 |
decreases activity |
ISO |
Maneb results in decreased activity of SIRT1 protein |
CTD |
PMID:21251949 |
|
NCBI chr20:26,831,971...26,851,587
Ensembl chr20:26,833,357...26,852,199
|
|
G |
Sirt2 |
sirtuin 2 |
decreases activity |
ISO |
Maneb results in decreased activity of SIRT2 protein |
CTD |
PMID:21251949 |
|
NCBI chr 1:86,948,866...86,971,954
Ensembl chr 1:86,948,918...86,971,952
|
|
G |
Sirt3 |
sirtuin 3 |
decreases activity |
ISO |
Maneb results in decreased activity of SIRT3 protein |
CTD |
PMID:21251949 |
|
NCBI chr 1:213,613,502...213,636,061
Ensembl chr 1:213,613,513...213,635,546
|
|
G |
Slc17a8 |
solute carrier family 17 member 8 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of SLC17A8 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 7:30,215,231...30,274,993
Ensembl chr 7:30,216,104...30,274,984
|
|
G |
Slc18a2 |
solute carrier family 18 member A2 |
multiple interactions decreases expression |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of SLC18A2 mRNA; Ketoconazole inhibits the reaction [Maneb results in decreased expression of SLC18A2 protein]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of SLC18A2 mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of SLC18A2 mRNA] |
CTD |
PMID:18386188 PMID:20964710 PMID:22334051 |
|
NCBI chr 1:280,397,831...280,457,968
Ensembl chr 1:280,423,079...280,457,148
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of SLC22A2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of SLC22A2 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 1:48,318,025...48,360,219
Ensembl chr 1:48,317,995...48,360,261
|
|
G |
Slc40a1 |
solute carrier family 40 member 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of SLC40A1 protein; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of SLC40A1 protein] |
CTD |
PMID:30797899 |
|
NCBI chr 9:52,819,451...52,830,461
Ensembl chr 9:52,894,365...52,912,293
|
|
G |
Slc5a7 |
solute carrier family 5 member 7 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of SLC5A7 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 9:5,294,377...5,330,822
Ensembl chr 9:5,294,381...5,330,815
|
|
G |
Slc6a2 |
solute carrier family 6 member 2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of SLC6A2 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr19:15,391,682...15,431,274
Ensembl chr19:15,391,581...15,431,274
|
|
G |
Slc6a3 |
solute carrier family 6 member 3 |
multiple interactions affects response to substance |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of SLC6A3 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of SLC6A3 protein SLC6A3 gene polymorphism affects the susceptibility to Maneb |
CTD |
PMID:11124998 PMID:18386188 PMID:19590691 |
|
NCBI chr 1:32,323,011...32,363,983
Ensembl chr 1:32,321,580...32,363,983
|
|
G |
Slc8a1 |
solute carrier family 8 member A1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of SLC8A1 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 6:4,244,076...4,564,262
Ensembl chr 6:4,258,991...4,520,604
|
|
G |
Snca |
synuclein alpha |
multiple interactions increases response to substance |
ISO |
[Paraquat co-treated with Maneb] promotes the reaction [SNCA protein binds to SNCA protein]; [Paraquat co-treated with Maneb] results in increased expression of SNCA protein; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of ADORA1 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of APBB1 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of ASCL1 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of BMP2 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of BMP4 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of DLL1 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of DRD2 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of DRD5 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of HEYL mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of PAX5 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of SEMA4D mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of VEGFA mRNA; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] promotes the reaction [SNCA protein binds to SNCA protein]]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of SNCA protein]; SNCA protein inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CDK5RAP2 mRNA]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] promotes the reaction [SNCA protein binds to SNCA protein]] SNCA gene mutant form results in increased susceptibility to Maneb [Maneb promotes the reaction [SNCA gene mutant form results in increased susceptibility to Paraquat]] which results in increased abundance of Nitric Oxide; [Maneb promotes the reaction [SNCA gene mutant form results in increased susceptibility to Paraquat]] which results in increased metabolism of MEF2C protein; [Paraquat promotes the reaction [SNCA gene mutant form results in increased susceptibility to Maneb]] which results in increased abundance of Nitric Oxide; [Paraquat promotes the reaction [SNCA gene mutant form results in increased susceptibility to Maneb]] which results in increased metabolism of MEF2C protein; Maneb promotes the reaction [Paraquat results in increased expression of SNCA protein]; Maneb promotes the reaction [SNCA gene mutant form results in increased susceptibility to Paraquat]; Paraquat promotes the reaction [SNCA gene mutant form results in increased susceptibility to Maneb]; SNCA protein mutant form results in increased susceptibility to [Paraquat co-treated with Maneb]; SNCA protein results in increased susceptibility to [Maneb co-treated with Paraquat] |
CTD |
PMID:23017109 PMID:24290359 PMID:26498265 PMID:27324791 PMID:29568078 PMID:32375810 |
|
NCBI chr 4:90,782,412...90,883,236
Ensembl chr 4:90,782,374...90,882,285
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
ISO EXP |
SOD1 protein results in decreased susceptibility to [Paraquat co-treated with Maneb] [Maneb co-treated with Paraquat] results in increased expression of SOD1 mRNA [Paraquat co-treated with Maneb] results in decreased expression of SOD1 mRNA |
CTD |
PMID:15824117 PMID:18386188 PMID:29859004 |
|
NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions decreases expression |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of SOD2 protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of SOD2 protein]; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of SOD2 protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of SOD2 protein] Maneb results in decreased expression of SOD2 mRNA |
CTD |
PMID:23562983 PMID:26210702 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of STAT3 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of STAT3 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of STAT3 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
|
|
G |
Stat4 |
signal transducer and activator of transcription 4 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of STAT4 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of STAT4 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of STAT4 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 9:54,340,649...54,457,753
Ensembl chr 9:54,287,541...54,484,533
|
|
G |
Stmn1 |
stathmin 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of STMN1 protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of STMN1 protein]; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of STMN1 protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of STMN1 protein] |
CTD |
PMID:23562983 |
|
NCBI chr 5:152,680,412...152,686,807
Ensembl chr 5:152,680,407...152,686,806
|
|
G |
Ston2 |
stonin 2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of STON2 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 6:115,398,586...115,547,552
Ensembl chr 6:115,399,326...115,513,354
|
|
G |
Strbp |
spermatid perinuclear RNA binding protein |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of STRBP mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 3:21,817,680...21,956,988
Ensembl chr 3:21,828,298...21,904,270
|
|
G |
Sumo1 |
small ubiquitin-like modifier 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of SUMO1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 9:66,453,428...66,483,614
Ensembl chr 9:66,453,438...66,483,614
|
|
G |
Syt5 |
synaptotagmin 5 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of SYT5 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of SYT5 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of SYT5 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 1:72,859,806...72,867,934
Ensembl chr 1:72,860,218...72,867,930
|
|
G |
Tbck |
TBC1 domain containing kinase |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of TBCK mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 2:237,751,646...237,958,497
Ensembl chr 2:237,751,654...237,958,497
|
|
G |
Tecr |
trans-2,3-enoyl-CoA reductase |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of TECR mRNA |
CTD |
PMID:18386188 |
|
NCBI chr19:24,705,478...24,732,024
Ensembl chr19:24,705,481...24,732,024
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of TGFB1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TGFB1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TGFB1 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions decreases expression |
ISO EXP |
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TH protein]; [Paraquat co-treated with Maneb] results in decreased expression of TH protein; [Paraquat co-treated with Maneb] results in increased expression of TH protein; Genistein inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TH protein]; Ketoconazole inhibits the reaction [Maneb results in decreased expression of TH protein]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of TH protein]; pimagedine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TH protein]; prolinedithiocarbamate inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TH protein]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of TH protein] [Paraquat co-treated with Maneb] results in decreased expression of TH; [Paraquat co-treated with Maneb] results in decreased expression of TH mRNA; [Paraquat co-treated with Maneb] results in decreased expression of TH protein |
CTD |
PMID:11124998 PMID:18386188 PMID:20455021 PMID:20964710 PMID:22334051 PMID:24376148 PMID:24486957 PMID:29152652 |
|
NCBI chr 1:216,073,034...216,080,287
Ensembl chr 1:216,073,031...216,080,287
|
|
G |
Timm13 |
translocase of inner mitochondrial membrane 13 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of TIMM13 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 7:11,677,340...11,678,443
Ensembl chr 7:11,677,340...11,678,442
|
|
G |
Tmem42 |
transmembrane protein 42 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of TMEM42 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 8:132,105,965...132,108,462
Ensembl chr 8:132,105,443...132,108,462
|
|
G |
Tnf |
tumor necrosis factor |
increases expression multiple interactions |
EXP ISO |
Maneb results in increased expression of TNF mRNA [Maneb co-treated with Paraquat] results in increased expression of TNF mRNA; [Paraquat co-treated with Maneb] results in increased expression of TNF mRNA; acetovanillone inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TNF mRNA]; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA]; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TNF mRNA]; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TNF mRNA]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA] [Paraquat co-treated with Maneb] results in increased expression of TNF mRNA; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA]; Silymarin inhibits the reaction [Maneb results in increased expression of TNF mRNA] |
CTD |
PMID:23159886 PMID:23963992 PMID:28202386 PMID:29568078 PMID:30797899 PMID:32169474 PMID:32375810 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tnfaip3 |
TNF alpha induced protein 3 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of TNFAIP3 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TNFAIP3 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 1:14,401,103...14,416,369
Ensembl chr 1:14,402,913...14,412,807
|
|
G |
Tnr |
tenascin R |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of TNR mRNA |
CTD |
PMID:23017109 |
|
NCBI chr13:77,602,249...77,678,385
Ensembl chr13:77,485,113...77,678,437
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
3-bromo-7-nitroindazole inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TRP53 protein]; [Maneb co-treated with Paraquat] results in increased expression of TRP53 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of TRP53 protein; [Paraquat co-treated with Maneb] results in increased activity of TRP53 protein modified form; [Paraquat co-treated with Maneb] results in increased expression of TRP53 protein; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TRP53 mRNA]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of TRP53 protein]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased activity of TRP53 protein modified form]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TRP53 mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of TRP53 protein]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased activity of TRP53 protein modified form] |
CTD |
PMID:20964710 PMID:23963992 PMID:23985028 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Traf3ip2 |
Traf3 interacting protein 2 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of ACT1 protein |
CTD |
PMID:23562983 |
|
NCBI chr20:44,679,861...44,722,874
Ensembl chr20:44,680,449...44,722,872
|
|
G |
Traf6 |
TNF receptor associated factor 6 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of TRAF6 mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TRAF6 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 3:91,252,829...91,271,607
Ensembl chr 3:91,252,829...91,271,607
|
|
G |
Trpm3 |
transient receptor potential cation channel, subfamily M, member 3 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of TRPM3 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 1:239,741,572...240,757,583
Ensembl chr 1:240,355,149...240,757,583
|
|
G |
Tuba1a |
tubulin, alpha 1A |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of TUBA1A protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TUBA1A protein]; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TUBA1A protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TUBA1A protein] |
CTD |
PMID:23562983 |
|
NCBI chr 7:140,637,287...140,640,953
Ensembl chr 7:140,637,287...140,640,953
|
|
G |
Tuba1b |
tubulin, alpha 1B |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of TUBA1B mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 7:140,614,746...140,617,721
Ensembl chr 7:140,614,752...140,617,721
|
|
G |
Tubb5 |
tubulin, beta 5 class I |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of TUBB5 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of TUBB5 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr20:3,422,448...3,426,420
Ensembl chr20:3,422,461...3,426,371
|
|
G |
Txn1 |
thioredoxin 1 |
increases expression |
ISO |
[Maneb results in increased expression of NFE2L2 protein] which results in increased expression of TXN1 mRNA |
CTD |
PMID:21402726 |
|
NCBI chr 5:75,049,735...75,057,731
Ensembl chr 5:75,049,747...75,057,752
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
increases expression |
ISO |
[Maneb results in increased expression of NFE2L2 protein] which results in increased expression of TXNRD1 mRNA |
CTD |
PMID:21402726 |
|
NCBI chr 7:26,946,124...26,984,400
Ensembl chr 7:26,946,125...26,984,400
|
|
G |
Uba1 |
ubiquitin-like modifier activating enzyme 1 |
multiple interactions |
ISO |
Maneb results in decreased activity of and results in decreased ubiquitination of UBA1 protein |
CTD |
PMID:25714994 |
|
NCBI chr X:1,723,135...1,745,147
Ensembl chr X:1,723,174...1,741,701
|
|
G |
Ubb |
ubiquitin B |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of UBB mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of UBB mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of UBB mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr10:48,880,231...48,881,896
Ensembl chr10:48,881,049...48,881,881
|
|
G |
Ubc |
ubiquitin C |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of UBC mRNA |
CTD |
PMID:18386188 |
|
NCBI chr12:36,638,457...36,642,734
Ensembl chr12:36,638,457...36,642,734
|
|
G |
Ubxn7 |
UBX domain protein 7 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of UBXN7 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr11:71,662,786...71,695,031
|
|
G |
Uchl1 |
ubiquitin C-terminal hydrolase L1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of UCHL1 protein; [Paraquat co-treated with Maneb] results in decreased expression of UCHL1 mRNA |
CTD |
PMID:18386188 PMID:23562983 |
|
NCBI chr14:43,133,224...43,143,942
Ensembl chr14:43,133,218...43,143,973
|
|
G |
Uchl5 |
ubiquitin C-terminal hydrolase L5 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of UCHL5 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr13:60,568,102...60,603,812
Ensembl chr13:60,545,635...60,603,811
|
|
G |
Unc13c |
unc-13 homolog C |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of UNC13C mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 8:80,202,736...80,656,363
Ensembl chr 8:80,203,609...80,631,926
|
|
G |
Upf3b |
UPF3B, regulator of nonsense mediated mRNA decay |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of UPF3B mRNA |
CTD |
PMID:18386188 |
|
NCBI chr X:123,713,327...123,731,431
Ensembl chr X:123,713,339...123,731,385
|
|
G |
Uqcrc1 |
ubiquinol-cytochrome c reductase core protein 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of UQCRC1 protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of UQCRC1 protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of UQCRC1 protein] |
CTD |
PMID:23562983 |
|
NCBI chr 8:117,679,328...117,691,073
Ensembl chr 8:117,679,278...117,691,071
|
|
G |
Vamp5 |
vesicle-associated membrane protein 5 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of VAMP5 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of VAMP5 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of VAMP5 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 4:100,231,561...100,232,560
Ensembl chr 4:100,231,561...100,232,559
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of VEGFA mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of VEGFA mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
G |
Vps45 |
vacuolar protein sorting 45 homolog |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of VPS45 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of VPS45 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 2:198,123,747...198,184,739
Ensembl chr 2:198,123,748...198,184,739
|
|
G |
Wnt1 |
Wnt family member 1 |
multiple interactions |
EXP |
[Paraquat co-treated with Maneb] results in decreased expression of WNT1 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of WNT1 protein |
CTD |
PMID:29152652 |
|
NCBI chr 7:140,464,999...140,469,046
Ensembl chr 7:140,464,999...140,469,046
|
|
G |
Wnt5a |
Wnt family member 5A |
multiple interactions |
EXP |
[Paraquat co-treated with Maneb] results in increased expression of WNT5A mRNA; [Paraquat co-treated with Maneb] results in increased expression of WNT5A protein |
CTD |
PMID:29152652 |
|
NCBI chr16:4,469,451...4,490,271
Ensembl chr16:4,469,468...4,489,860
|
|
G |
Zbtb44 |
zinc finger and BTB domain containing 44 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of ZBTB44 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 8:32,165,388...32,223,341
Ensembl chr 8:32,165,810...32,217,476
|
|
G |
Zfp580 |
zinc finger protein 580 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of ZFP580 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 1:72,338,468...72,340,636
Ensembl chr 1:72,338,877...72,339,395
|
|
G |
Zhx3 |
zinc fingers and homeoboxes 3 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of ZHX3 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 3:156,759,820...156,868,173
Ensembl chr 3:156,764,751...156,777,999
|
|
|
G |
Ache |
acetylcholinesterase |
decreases expression |
EXP |
manganese dioxide results in decreased expression of ACHE protein |
CTD |
PMID:23702825 |
|
NCBI chr12:22,472,358...22,477,052
Ensembl chr12:22,472,358...22,478,753
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
increases activity |
EXP |
manganese dioxide results in increased activity of GPT protein |
CTD |
PMID:23702825 |
|
NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
|
|
|
G |
Abca5 |
ATP binding cassette subfamily A member 5 |
decreases expression |
ISO |
Manganese results in decreased expression of ABCA5 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr10:98,573,226...98,645,028
Ensembl chr10:98,576,039...98,644,938
|
|
G |
Abca9 |
ATP binding cassette subfamily A member 9 |
increases expression |
ISO |
Manganese results in increased expression of ABCA9 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr10:98,412,263...98,472,258
Ensembl chr10:98,412,263...98,469,799
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases activity increases expression multiple interactions |
ISO EXP |
Manganese results in increased activity of ABCB1 protein Manganese results in increased expression of ABCB1A mRNA [Manganese results in increased activity of ABCB1 protein] which results in increased hydrolysis of Adenosine Triphosphate |
CTD |
PMID:2900677 PMID:26745496 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcc6 |
ATP binding cassette subfamily C member 6 |
multiple interactions |
EXP |
Manganese promotes the reaction [8-azidoadenosine 5'-triphosphate binds to ABCC6 protein]; Manganese promotes the reaction [beryllium fluoride promotes the reaction [8-azidoadenosine 5'-triphosphate binds to ABCC6 protein]] |
CTD |
PMID:12069597 |
|
NCBI chr 1:101,954,786...102,013,252
Ensembl chr 1:101,959,540...102,013,243
|
|
G |
Abcc8 |
ATP binding cassette subfamily C member 8 |
multiple interactions |
ISO |
[manganese chloride results in increased abundance of Manganese] which results in increased expression of ABCC8 protein |
CTD |
PMID:32659473 |
|
NCBI chr 1:102,110,708...102,191,287
Ensembl chr 1:102,110,708...102,191,287
|
|
G |
Abi2 |
abl-interactor 2 |
increases expression |
ISO |
Manganese results in increased expression of ABI2 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 9:67,234,612...67,284,504
Ensembl chr 9:67,234,303...67,282,600
|
|
G |
Acat2 |
acetyl-CoA acetyltransferase 2 |
decreases expression |
ISO |
Manganese results in decreased expression of ACAT2 mRNA |
CTD |
PMID:23499988 |
|
NCBI chr 1:47,972,399...47,992,654
Ensembl chr 1:47,972,399...47,992,653
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions increases activity |
EXP ISO |
[manganese chloride results in increased abundance of Manganese] promotes the reaction [Ethanol results in increased activity of ACHE protein]; [manganese chloride results in increased abundance of Manganese] which results in increased activity of ACHE protein; Ethanol promotes the reaction [[manganese chloride results in increased abundance of Manganese] which results in increased activity of ACHE protein]; Taurine inhibits the reaction [Manganese results in increased activity of ACHE protein] [manganese chloride results in increased abundance of Manganese] which results in decreased activity of ACHE protein; [manganese chloride results in increased abundance of Manganese] which results in increased activity of ACHE protein; [manganese chloride results in increased abundance of Manganese] which results in increased expression of ACHE mRNA alternative form |
CTD |
PMID:24885898 PMID:30738988 PMID:30844427 PMID:32445656 |
|
NCBI chr12:22,472,358...22,477,052
Ensembl chr12:22,472,358...22,478,753
|
|
G |
Aco1 |
aconitase 1 |
decreases activity increases activity multiple interactions |
EXP ISO |
Manganese results in decreased activity of ACO1 protein Manganese results in increased activity of ACO1 protein Manganese results in increased stability of [ACO1 protein binds to SLC11A2 mRNA] |
CTD |
PMID:16386771 PMID:16545456 PMID:16568477 PMID:16729984 PMID:17469137 |
|
NCBI chr 5:56,425,076...56,481,218
Ensembl chr 5:56,425,024...56,481,218
|
|
G |
Aco2 |
aconitase 2 |
multiple interactions decreases activity decreases expression |
ISO EXP |
ferric ammonium citrate inhibits the reaction [Manganese results in decreased activity of ACO2 protein] Iron inhibits the reaction [Manganese results in decreased activity of ACO2 protein] Manganese results in decreased expression of ACO2 mRNA; Manganese results in decreased expression of ACO2 protein |
CTD |
PMID:9675333 PMID:16625280 PMID:17469137 |
|
NCBI chr 7:123,102,493...123,145,608
Ensembl chr 7:123,102,468...123,145,635
|
|
G |
Acta1 |
actin, alpha 1, skeletal muscle |
decreases expression |
EXP |
Manganese results in decreased expression of ACTA1 mRNA |
CTD |
PMID:26745496 |
|
NCBI chr19:56,674,072...56,677,084
Ensembl chr19:56,674,074...56,677,084
|
|
G |
Actr3 |
actin related protein 3 |
affects expression |
EXP |
Manganese affects the expression of ACTR3 protein |
CTD |
PMID:24885898 |
|
NCBI chr13:41,695,520...41,738,622
Ensembl chr13:41,695,183...41,738,658
|
|
G |
Adgre1 |
adhesion G protein-coupled receptor E1 |
increases expression |
EXP |
Manganese results in increased expression of ADGRE1 mRNA |
CTD |
PMID:20224926 |
|
NCBI chr 9:9,431,888...9,585,883
Ensembl chr 9:9,431,860...9,585,865
|
|
G |
Adm |
adrenomedullin |
increases expression |
ISO |
Manganese results in increased expression of ADM mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 1:175,443,189...175,447,260
Ensembl chr 1:175,445,088...175,447,259
|
|
G |
Afp |
alpha-fetoprotein |
decreases expression |
EXP |
Manganese results in decreased expression of AFP mRNA |
CTD |
PMID:26745496 |
|
NCBI chr14:19,141,755...19,159,919
Ensembl chr14:19,141,755...19,159,923
|
|
G |
Akap7 |
A-kinase anchoring protein 7 |
decreases expression |
ISO |
Manganese results in decreased expression of AKAP7 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 1:21,129,213...21,263,850
Ensembl chr 1:21,141,970...21,263,850
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases expression multiple interactions increases phosphorylation |
ISO EXP |
Manganese results in decreased expression of AKT1 protein [manganese chloride results in increased abundance of Manganese] which results in decreased phosphorylation of AKT1 protein; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [[manganese chloride results in increased abundance of Manganese] which results in decreased phosphorylation of AKT1 protein] NTF3 protein inhibits the reaction [[manganese chloride results in increased abundance of Manganese] which results in decreased phosphorylation of AKT1 protein] Manganese results in increased phosphorylation of AKT1 protein |
CTD |
PMID:17043766 PMID:24845367 PMID:31676349 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Angpt2 |
angiopoietin 2 |
decreases expression |
EXP |
Manganese results in decreased expression of ANGPT2 mRNA |
CTD |
PMID:26745496 |
|
NCBI chr16:75,966,480...76,016,147
Ensembl chr16:75,966,352...76,016,195
|
|
G |
Angptl4 |
angiopoietin-like 4 |
increases expression |
ISO |
Manganese results in increased expression of ANGPTL4 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 7:18,627,814...18,634,043
Ensembl chr 7:18,627,808...18,634,079
|
|
G |
Ap3b2 |
adaptor related protein complex 3 subunit beta 2 |
increases expression |
ISO |
Manganese results in increased expression of AP3B2 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 1:143,284,041...143,315,846
Ensembl chr 1:143,283,996...143,315,633
|
|
G |
App |
amyloid beta precursor protein |
increases expression |
ISO |
Manganese results in increased expression of APP mRNA |
CTD |
PMID:18583042 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Aqp4 |
aquaporin 4 |
multiple interactions |
EXP |
Antioxidants inhibits the reaction [Manganese results in increased expression of AQP4 protein] |
CTD |
PMID:20648640 |
|
NCBI chr18:6,766,009...6,782,757
Ensembl chr18:6,765,945...6,782,996
|
|
G |
Arg1 |
arginase 1 |
affects binding |
ISO EXP |
Manganese binds to ARG1 protein |
CTD |
PMID:15248756 PMID:18802628 |
|
NCBI chr 1:21,525,421...21,537,872
Ensembl chr 1:21,525,421...21,537,863
|
|
G |
Arhgdia |
Rho GDP dissociation inhibitor alpha |
decreases expression |
ISO |
Manganese results in decreased expression of ARHGDIA mRNA |
CTD |
PMID:17175027 |
|
NCBI chr10:109,754,012...109,757,506
Ensembl chr10:109,754,004...109,757,550
|
|
G |
Arhgef4 |
Rho guanine nucleotide exchange factor 4 |
increases expression |
ISO |
Manganese results in increased expression of ARHGEF4 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 9:41,160,562...41,305,015
Ensembl chr 9:41,295,909...41,302,501
|
|
G |
Atf1 |
activating transcription factor 1 |
increases phosphorylation multiple interactions |
EXP |
Manganese results in increased phosphorylation of ATF1 protein SB 203580 inhibits the reaction [Manganese results in increased phosphorylation of ATF1 protein] |
CTD |
PMID:16787641 |
|
NCBI chr 7:141,882,261...141,924,790
Ensembl chr 7:141,882,251...141,924,788
|
|
G |
Atf6 |
activating transcription factor 6 |
decreases expression |
ISO |
Manganese results in decreased expression of ATF6 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr13:89,053,457...89,242,531
Ensembl chr13:89,055,983...89,242,443
|
|
G |
Atm |
ATM serine/threonine kinase |
decreases expression |
ISO |
Manganese results in decreased expression of ATM mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 8:58,015,938...58,119,973
Ensembl chr 8:58,015,940...58,120,045
|
|
G |
Atoh8 |
atonal bHLH transcription factor 8 |
decreases expression |
EXP |
Manganese results in decreased expression of ATOH8 mRNA |
CTD |
PMID:26745496 |
|
NCBI chr 4:100,067,341...100,099,517
Ensembl chr 4:100,067,341...100,099,517
|
|
G |
Atp13a2 |
ATPase cation transporting 13A2 |
affects response to substance decreases response to substance |
ISO |
ATP13A2 gene polymorphism affects the susceptibility to Manganese ATP13A2 protein results in decreased susceptibility to Manganese |
CTD |
PMID:22285144 PMID:22847264 |
|
NCBI chr 5:159,512,208...159,531,631
Ensembl chr 5:159,512,285...159,531,637
|
|
G |
Atp1a3 |
ATPase Na+/K+ transporting subunit alpha 3 |
decreases expression increases methylation |
ISO |
Manganese results in decreased expression of ATP1A3 mRNA Manganese results in increased methylation of ATP1A3 promoter |
CTD |
PMID:23976782 |
|
NCBI chr 1:81,852,423...81,881,565
Ensembl chr 1:81,852,429...81,881,549
|
|
G |
Atp7a |
ATPase copper transporting alpha |
affects localization decreases expression |
EXP |
Manganese affects the localization of ATP7A protein Manganese results in decreased expression of ATP7A mRNA; Manganese results in decreased expression of ATP7A protein |
CTD |
PMID:24614235 |
|
NCBI chr X:77,076,085...77,193,644
Ensembl chr X:77,076,106...77,193,644
|
|
G |
Atp7b |
ATPase copper transporting beta |
increases phosphorylation decreases expression affects localization |
ISO EXP |
Manganese results in increased phosphorylation of ATP7B protein Manganese results in decreased expression of ATP7B mRNA; Manganese results in decreased expression of ATP7B protein Manganese affects the localization of ATP7B protein |
CTD |
PMID:19405516 PMID:24614235 |
|
NCBI chr16:74,865,516...74,944,935
Ensembl chr16:74,865,516...74,945,286
|
|
G |
Atp8a1 |
ATPase phospholipid transporting 8A1 |
decreases expression |
ISO |
Manganese results in decreased expression of ATP8A1 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr14:41,972,398...42,210,555
Ensembl chr14:42,015,347...42,206,311
|
|
G |
Bace1 |
beta-secretase 1 |
increases expression |
ISO |
Manganese results in increased expression of BACE1 mRNA |
CTD |
PMID:18583042 |
|
NCBI chr 8:50,140,092...50,162,388
Ensembl chr 8:50,139,997...50,162,361
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
EXP ISO |
[manganese chloride results in increased abundance of Manganese] promotes the reaction [Ethanol results in increased expression of BAX protein]; [manganese chloride results in increased abundance of Manganese] which results in increased expression of BAX protein; [Manganese co-treated with NGF protein] results in increased expression of BAX protein; Ethanol promotes the reaction [[manganese chloride results in increased abundance of Manganese] which results in increased expression of BAX protein]; PPM1D protein inhibits the reaction [[Manganese co-treated with NGF protein] results in increased expression of BAX protein]; Rolipram inhibits the reaction [Manganese results in increased expression of BAX protein] [manganese chloride results in increased abundance of Manganese] which results in increased expression of BAX protein; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [[manganese chloride results in increased abundance of Manganese] which results in increased expression of BAX protein] NTF3 protein inhibits the reaction [[manganese chloride results in increased abundance of Manganese] which results in increased expression of BAX protein] |
CTD |
PMID:25027559 PMID:25791630 PMID:30844427 PMID:30951808 PMID:31161640 PMID:31676349 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
EXP ISO |
[manganese chloride results in increased abundance of Manganese] promotes the reaction [Ethanol results in decreased expression of BCL2 protein]; [manganese chloride results in increased abundance of Manganese] which results in decreased expression of BCL2 protein; Ethanol promotes the reaction [[manganese chloride results in increased abundance of Manganese] which results in decreased expression of BCL2 protein]; Rolipram inhibits the reaction [Manganese results in decreased expression of BCL2 protein] |
CTD |
PMID:30844427 PMID:30951808 PMID:31161640 PMID:31676349 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression multiple interactions |
EXP |
Manganese results in decreased expression of BCL2L1 protein [Manganese co-treated with NGF protein] results in decreased expression of BCL2L1 protein; PPM1D protein inhibits the reaction [[Manganese co-treated with NGF protein] results in decreased expression of BCL2L1 protein] |
CTD |
PMID:25791630 |
|
NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions decreases expression |
EXP ISO |
[Curcumin co-treated with Manganese] inhibits the reaction [Kainic Acid results in increased expression of BDNF mRNA]; [diacetylcurcumin co-treated with Manganese] inhibits the reaction [Kainic Acid results in increased expression of BDNF mRNA]; [manganese chloride results in increased abundance of Manganese] which results in decreased expression of BDNF protein; [manganese chloride results in increased abundance of Manganese] which results in increased expression of BDNF mRNA; CREB1 protein affects the reaction [[manganese chloride results in increased abundance of Manganese] which results in increased expression of BDNF mRNA]; Rolipram inhibits the reaction [Manganese results in decreased expression of BDNF protein] Manganese results in decreased expression of BDNF mRNA; Manganese results in decreased expression of BDNF protein |
CTD |
PMID:17827730 PMID:25099302 PMID:29205667 PMID:30951808 PMID:31161640 PMID:32659473 |
|
NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
multiple interactions |
ISO |
Antioxidants inhibits the reaction [Manganese results in increased expression of BNIP3 protein] |
CTD |
PMID:19442826 |
|
NCBI chr 1:211,248,098...211,265,282
Ensembl chr 1:211,248,098...211,265,282
|
|
G |
Bub1 |
BUB1 mitotic checkpoint serine/threonine kinase |
decreases expression |
ISO |
Manganese results in decreased expression of BUB1 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 3:120,373,604...120,404,910
Ensembl chr 3:120,373,604...120,404,910
|
|
G |
Ca8 |
carbonic anhydrase 8 |
increases expression |
EXP |
Manganese results in increased expression of CAR8 mRNA |
CTD |
PMID:26745496 |
|
NCBI chr 5:21,249,018...21,345,810
Ensembl chr 5:21,249,020...21,345,810
|
|
G |
Calcoco2 |
calcium binding and coiled-coil domain 2 |
increases expression |
ISO |
Manganese results in increased expression of CALCOCO2 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr10:83,935,087...83,963,750
|
|
G |
Calr |
calreticulin |
affects expression |
EXP |
Manganese affects the expression of CALR protein |
CTD |
PMID:24885898 |
|
NCBI chr19:25,956,771...25,961,666
Ensembl chr19:25,956,771...25,961,666
|
|
G |
Camk2a |
calcium/calmodulin-dependent protein kinase II alpha |
decreases phosphorylation |
EXP |
Manganese results in decreased phosphorylation of CAMK2A protein |
CTD |
PMID:26616912 |
|
NCBI chr18:56,193,978...56,295,869
Ensembl chr18:56,193,978...56,295,869
|
|
G |
Capn1 |
calpain 1 |
increases activity multiple interactions |
EXP |
Manganese results in increased activity of CAPN1 protein calpain inhibitor III inhibits the reaction [Manganese results in increased activity of CAPN1 protein] |
CTD |
PMID:21985864 |
|
NCBI chr 1:221,346,081...221,370,965
Ensembl chr 1:221,346,066...221,370,322
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity increases expression increases cleavage |
EXP ISO |
[manganese chloride results in increased abundance of Manganese] promotes the reaction [Ethanol results in increased expression of CASP3 protein]; [manganese chloride results in increased abundance of Manganese] which results in increased cleavage of CASP3 protein; [manganese chloride results in increased abundance of Manganese] which results in increased expression of CASP3 protein; aspartyl-glutamyl-valyl-aspartal inhibits the reaction [Manganese results in increased activity of CASP3 protein]; Deferoxamine inhibits the reaction [Manganese results in increased activity of CASP3 protein]; Ethanol promotes the reaction [[manganese chloride results in increased abundance of Manganese] which results in increased expression of CASP3 protein]; GW 506033X inhibits the reaction [[manganese chloride results in increased abundance of Manganese] which results in increased cleavage of CASP3 protein]; Manganese promotes the reaction [SP1 protein modified form binds to CASP3 promoter]; Manganese results in increased expression of and results in increased cleavage of CASP3 protein; pyrazolanthrone inhibits the reaction [[manganese chloride results in increased abundance of Manganese] which results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [Manganese results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [Manganese results in increased expression of CASP3 protein]; quinoline-val-asp(OMe)-CH2-OPH inhibits the reaction [Manganese results in increased activity of CASP3 protein]; rhodioloside inhibits the reaction [[manganese chloride results in increased abundance of Manganese] which results in increased cleavage of CASP3 protein]; U 0126 inhibits the reaction [Manganese results in increased expression of CASP3 mRNA]; U 0126 inhibits the reaction [Manganese results in increased expression of CASP3 protein] SNCA protein inhibits the reaction [Manganese results in increased activity of CASP3 protein] Manganese results in increased expression of CASP3 mRNA; Manganese results in increased expression of CASP3 protein |
CTD |
PMID:11933051 PMID:16787641 PMID:21985864 PMID:22427945 PMID:22841634 PMID:22975163 PMID:25027559 PMID:25416158 PMID:30844427 PMID:30991096 PMID:31161640 PMID:31676349 PMID:32574669 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp7 |
caspase 7 |
increases activity |
EXP |
Manganese results in increased activity of CASP7 protein |
CTD |
PMID:22427945 |
|
NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
|
|
G |
Casp8 |
caspase 8 |
increases activity multiple interactions |
EXP |
Manganese results in increased activity of CASP8 protein Rolipram inhibits the reaction [Manganese results in increased activity of CASP8 protein] |
CTD |
PMID:31161640 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
increases cleavage increases activity multiple interactions |
EXP ISO |
Manganese results in increased cleavage of CASP9 protein Manganese results in increased activity of CASP9 protein SNCA protein inhibits the reaction [Manganese results in increased activity of CASP9 protein] |
CTD |
PMID:16787641 PMID:25416158 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cat |
catalase |
multiple interactions decreases activity |
ISO EXP |
[manganese chloride results in increased abundance of Manganese] which results in decreased activity of CAT protein; CAT protein inhibits the reaction [[[PRNP protein binds to Manganese] which co-treated with Hydrogen Peroxide] results in increased cleavage of [PRNP protein binds to PRNP protein]] Manganese results in decreased activity of CAT protein [Arsenic co-treated with Cadmium co-treated with Lead co-treated with Mercury co-treated with Chromium co-treated with Nickel co-treated with Manganese co-treated with Iron] results in decreased activity of CAT protein; [manganese chloride results in increased abundance of Manganese] promotes the reaction [Ethanol results in decreased activity of CAT protein]; [manganese chloride results in increased abundance of Manganese] which results in decreased activity of CAT protein; CAT protein inhibits the reaction [Manganese results in increased expression of SLC12A2 protein]; CAT protein inhibits the reaction [Manganese results in increased phosphorylation of and results in increased activity of SLC12A2 protein]; Ethanol promotes the reaction [[manganese chloride results in increased abundance of Manganese] which results in decreased activity of CAT protein]; Silymarin inhibits the reaction [Manganese results in decreased activity of CAT protein] |
CTD |
PMID:16595185 PMID:17176674 PMID:23339144 PMID:25817889 PMID:30844427 PMID:32445656 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Cav1 |
caveolin 1 |
decreases expression |
ISO |
Manganese results in decreased expression of CAV1 mRNA; Manganese results in decreased expression of CAV1 protein |
CTD |
PMID:23499988 PMID:23597857 |
|
NCBI chr 4:44,597,123...44,630,206
Ensembl chr 4:44,597,123...44,630,200
|
|
G |
Cav3 |
caveolin 3 |
decreases expression |
ISO |
Manganese results in decreased expression of CAV3 mRNA; Manganese results in decreased expression of CAV3 protein |
CTD |
PMID:23597857 |
|
NCBI chr 4:144,382,945...144,398,919
Ensembl chr 4:144,382,945...144,398,917
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression |
EXP |
Manganese results in increased expression of CCL2 mRNA |
CTD |
PMID:19782702 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl7 |
C-C motif chemokine ligand 7 |
increases expression |
ISO |
Manganese results in increased expression of CCL7 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr10:69,423,083...69,424,933
Ensembl chr10:69,423,086...69,424,979
|
|
G |
Ccna1 |
cyclin A1 |
increases expression |
EXP |
Manganese results in increased expression of CCNA1 mRNA |
CTD |
PMID:26745496 |
|
NCBI chr 2:144,456,689...144,503,570
Ensembl chr 2:144,458,153...144,467,912
|
|
G |
Ccnb2 |
cyclin B2 |
decreases expression |
ISO |
Manganese results in decreased expression of CCNB2 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 8:76,847,972...76,861,165
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression |
EXP |
Manganese results in increased expression of CCND1 mRNA |
CTD |
PMID:23997110 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Cd48 |
Cd48 molecule |
increases expression |
ISO |
Manganese results in increased expression of CD48 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr13:90,116,601...90,140,371
Ensembl chr13:90,116,843...90,140,371
|
|
G |
Cd8b |
CD8b molecule |
increases expression |
ISO |
Manganese results in increased expression of CD8B mRNA; Manganese results in increased expression of CD8B1 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 4:99,185,960...99,201,887
Ensembl chr 4:99,185,885...99,202,023
|
|
G |
Cdkn2c |
cyclin-dependent kinase inhibitor 2C |
decreases expression |
ISO |
Manganese results in decreased expression of CDKN2C mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 5:129,347,731...129,352,886
Ensembl chr 5:129,347,732...129,352,886
|
|
G |
Cdkn3 |
cyclin-dependent kinase inhibitor 3 |
decreases expression |
ISO |
Manganese results in decreased expression of CDKN3 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr15:23,553,171...23,564,538
Ensembl chr15:23,553,128...23,564,535
|
|
G |
Cebpd |
CCAAT/enhancer binding protein delta |
increases expression |
ISO |
Manganese results in increased expression of CEBPD mRNA |
CTD |
PMID:17175027 |
|
NCBI chr11:89,008,008...89,009,146
Ensembl chr11:89,008,008...89,009,146
|
|
G |
Celsr1 |
cadherin, EGF LAG seven-pass G-type receptor 1 |
increases expression |
ISO |
Manganese results in increased expression of CELSR1 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 7:126,774,010...126,914,085
Ensembl chr 7:126,775,516...126,913,585
|
|
G |
Cep128 |
centrosomal protein 128 |
decreases expression |
ISO |
Manganese results in decreased expression of CEP128 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 6:114,759,474...115,158,004
Ensembl chr 6:114,759,474...115,157,854
|
|
G |
Chat |
choline O-acetyltransferase |
decreases activity multiple interactions |
EXP ISO |
Manganese results in decreased activity of CHAT protein [manganese chloride results in increased abundance of Manganese] which results in decreased activity of CHAT protein Taurine inhibits the reaction [Manganese results in decreased activity of CHAT protein] |
CTD |
PMID:24885898 PMID:30738988 |
|
NCBI chr16:8,576,858...8,686,131
Ensembl chr16:8,577,840...8,686,131
|
|
G |
Cks2 |
CDC28 protein kinase regulatory subunit 2 |
decreases expression |
ISO |
Manganese results in decreased expression of CKS2 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr17:13,587,664...13,593,423
Ensembl chr17:13,587,665...13,593,423
|
|
G |
Cldn23 |
claudin 23 |
increases expression |
EXP |
Manganese results in increased expression of CLDN23 mRNA |
CTD |
PMID:26745496 |
|
NCBI chr16:59,988,603...59,990,327
Ensembl chr16:59,988,603...59,990,326
|
|
G |
Cln6 |
CLN6, transmembrane ER protein |
increases abundance |
ISO |
CLN6 gene mutant form results in increased abundance of Manganese |
CTD |
PMID:23789114 |
|
NCBI chr 8:67,733,215...67,748,170
Ensembl chr 8:67,733,215...67,748,172
|
|
G |
Cnot2 |
CCR4-NOT transcription complex, subunit 2 |
decreases expression |
ISO |
Manganese results in decreased expression of CNOT2 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 7:59,526,105...59,617,307
Ensembl chr 7:59,527,124...59,587,385
|
|
G |
Cnot6l |
CCR4-NOT transcription complex, subunit 6-like |
increases expression |
ISO |
Manganese results in increased expression of CNOT6L mRNA |
CTD |
PMID:17175027 |
|
NCBI chr14:15,059,101...15,148,255
Ensembl chr14:15,059,387...15,146,586
|
|
G |
Col12a1 |
collagen type XII alpha 1 chain |
decreases expression |
ISO |
Manganese results in decreased expression of COL12A1 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 8:87,042,820...87,150,701
Ensembl chr 8:87,040,799...87,158,368
|
|
G |
Cpm |
carboxypeptidase M |
decreases expression |
ISO |
Manganese results in decreased expression of CPM mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 7:60,654,350...60,714,620
Ensembl chr 7:60,654,350...60,714,620
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
increases phosphorylation decreases phosphorylation multiple interactions decreases expression |
EXP ISO |
Manganese results in increased phosphorylation of CREB1 protein Manganese results in decreased phosphorylation of CREB1 protein [manganese chloride results in increased abundance of Manganese] which results in decreased expression of CREB1 protein; NTF3 protein inhibits the reaction [[manganese chloride results in increased abundance of Manganese] which results in decreased phosphorylation of CREB1 protein] [manganese chloride results in increased abundance of Manganese] which results in decreased phosphorylation of CREB1 protein; [manganese chloride results in increased abundance of Manganese] which results in increased phosphorylation of CREB1 protein; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [[manganese chloride results in increased abundance of Manganese] which results in decreased phosphorylation of CREB1 protein] Manganese results in decreased expression of CREB1 mRNA; Manganese results in decreased expression of CREB1 protein 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[manganese chloride results in increased abundance of Manganese] which results in increased phosphorylation of CREB1 protein]; [manganese chloride results in increased abundance of Manganese] which results in increased phosphorylation of CREB1 protein; CREB1 protein affects the reaction [[manganese chloride results in increased abundance of Manganese] which results in increased expression of BDNF mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[manganese chloride results in increased abundance of Manganese] which results in increased phosphorylation of CREB1 protein]; Rolipram inhibits the reaction [Manganese results in decreased phosphorylation of CREB1 protein]; SB 203580 inhibits the reaction [[manganese chloride results in increased abundance of Manganese] which results in increased phosphorylation of CREB1 protein]; SB 203580 inhibits the reaction [Manganese results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:16787641 PMID:29205667 PMID:30951808 PMID:31161640 PMID:31676349 PMID:32659473 |
|
NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
|
|
G |
Crh |
corticotropin releasing hormone |
multiple interactions |
EXP |
CRH protein inhibits the reaction [Manganese results in increased chemical synthesis of Cyclic AMP] |
CTD |
PMID:2153673 |
|
NCBI chr 2:104,459,999...104,461,863
Ensembl chr 2:104,459,999...104,461,863
|
|
G |
Crym |
crystallin, mu |
affects expression |
EXP |
Manganese affects the expression of CRYM protein |
CTD |
PMID:24885898 |
|
NCBI chr 1:189,944,895...189,960,069
Ensembl chr 1:189,944,895...189,960,073
|
|
G |
Csrp3 |
cysteine and glycine rich protein 3 |
increases expression |
EXP |
Manganese results in increased expression of CSRP3 mRNA |
CTD |
PMID:26745496 |
|
NCBI chr 1:104,147,205...104,166,389
Ensembl chr 1:104,147,206...104,166,367
|
|
G |
Ctnna1 |
catenin alpha 1 |
decreases expression |
ISO |
Manganese results in decreased expression of CTNNA1 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr18:27,923,229...28,055,972
Ensembl chr18:27,923,572...28,055,960
|
|
G |
Ctnnb1 |
catenin beta 1 |
decreases expression |
ISO |
Manganese results in decreased expression of CTNNB1 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
decreases expression |
ISO |
Manganese results in decreased expression of CXCL12 mRNA |
CTD |
PMID:23499988 |
|
NCBI chr 4:149,261,044...149,273,891
Ensembl chr 4:149,261,044...149,273,891
|
|
G |
Cxcl14 |
C-X-C motif chemokine ligand 14 |
increases expression |
ISO |
Manganese results in increased expression of CXCL14 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr17:9,109,731...9,117,754
Ensembl chr17:9,109,731...9,117,750
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
increases expression |
ISO EXP |
Manganese results in increased expression of CXCL2 mRNA |
CTD |
PMID:17175027 PMID:19782702 PMID:20224926 |
|
NCBI chr14:18,731,346...18,733,391
Ensembl chr14:18,731,378...18,733,391
|
|
G |
Cxcl6 |
C-X-C motif chemokine ligand 6 |
increases expression |
ISO |
Manganese results in increased expression of CXCL6 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr14:18,860,201...18,920,839
Ensembl chr14:18,860,264...18,862,407
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions affects localization |
ISO EXP |
SNCA protein inhibits the reaction [Manganese affects the localization of CYCS protein] |
CTD |
PMID:25416158 |
|
NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
decreases expression |
EXP |
Manganese results in decreased expression of CYP11A1 protein |
CTD |
PMID:25981801 |
|
NCBI chr 8:62,798,317...62,809,848
Ensembl chr 8:62,779,875...62,809,893
|
|
G |
Cyp26b1 |
cytochrome P450, family 26, subfamily b, polypeptide 1 |
decreases expression |
EXP |
Manganese results in decreased expression of CYP26B1 mRNA |
CTD |
PMID:26745496 |
|
NCBI chr 4:116,261,796...116,278,615
Ensembl chr 4:116,261,796...116,278,615
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
decreases response to substance |
ISO |
CYP2D6 gene polymorphism results in decreased susceptibility to Manganese |
CTD |
PMID:12171760 |
|
NCBI chr 7:123,599,264...123,608,436
Ensembl chr 7:123,599,266...123,608,436
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions increases activity |
EXP |
[Manganese co-treated with Bilirubin] results in decreased activity of CYP7A1 protein Manganese results in increased activity of CYP7A1 protein |
CTD |
PMID:12700418 |
|
NCBI chr 5:19,358,734...19,368,431
Ensembl chr 5:19,358,734...19,368,431
|
|
G |
Dach2 |
dachshund family transcription factor 2 |
increases expression |
ISO |
Manganese results in increased expression of DACH2 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr X:84,924,570...85,484,150
Ensembl chr X:85,338,928...85,483,719
|
|
G |
Dctn3 |
dynactin subunit 3 |
affects expression |
EXP |
Manganese affects the expression of DCTN3 protein |
CTD |
PMID:24885898 |
|
NCBI chr 5:58,098,706...58,106,706
Ensembl chr 5:58,098,706...58,106,706
|
|
G |
Ddah1 |
dimethylarginine dimethylaminohydrolase 1 |
decreases expression multiple interactions |
ISO |
Manganese deficiency results in decreased expression of DDAH1 protein Paroxetine inhibits the reaction [Manganese deficiency results in decreased expression of DDAH1 protein] |
CTD |
PMID:21312047 |
|
NCBI chr 2:251,634,368...251,766,009
Ensembl chr 2:251,634,431...251,766,014
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions |
ISO EXP |
Manganese results in increased expression of DDIT3 protein [manganese chloride results in increased abundance of Manganese] which results in increased expression of DDIT3 mRNA Manganese results in increased expression of DDIT3 mRNA |
CTD |
PMID:21477646 PMID:23499988 PMID:32574669 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Dld |
dihydrolipoamide dehydrogenase |
decreases expression |
EXP |
Manganese results in decreased expression of DLD protein |
CTD |
PMID:25981801 |
|
NCBI chr 6:50,597,677...50,618,694
Ensembl chr 6:50,597,677...50,618,694
|
|
G |
Dnah14 |
dynein axonemal heavy chain 14 |
decreases expression |
ISO |
Manganese results in decreased expression of DNAH14 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr13:99,886,373...100,072,674 NCBI chr13:101,936,210...101,973,640
|
|
G |
Dnph1 |
2'-deoxynucleoside 5'-phosphate N-hydrolase 1 |
decreases expression |
ISO |
Manganese results in decreased expression of DNPH1 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 9:16,845,764...16,848,514
Ensembl chr 9:16,845,525...16,848,503
|
|
G |
Dpp4 |
dipeptidylpeptidase 4 |
increases expression |
ISO |
Manganese results in increased expression of DPP4 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 3:48,291,055...48,372,672
Ensembl chr 3:48,291,055...48,372,672
|
|
G |
Dr1 |
down-regulator of transcription 1 |
decreases expression |
ISO |
Manganese results in decreased expression of DR1 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr14:2,463,651...2,475,004
Ensembl chr14:2,463,643...2,474,780
|
|
G |
Drd2 |
dopamine receptor D2 |
decreases expression |
EXP |
Manganese results in decreased expression of DRD2 mRNA |
CTD |
PMID:20224926 |
|
NCBI chr 8:53,678,777...53,743,643
Ensembl chr 8:53,678,777...53,743,642
|
|
G |
Dscaml1 |
DS cell adhesion molecule-like 1 |
increases expression |
EXP |
Manganese results in increased expression of DSCAML1 mRNA |
CTD |
PMID:26745496 |
|
NCBI chr 8:49,733,835...50,056,115
Ensembl chr 8:49,737,798...50,055,560
|
|
G |
Dspp |
dentin sialophosphoprotein |
increases expression |
ISO |
Manganese results in increased expression of DSPP mRNA |
CTD |
PMID:17175027 |
|
NCBI chr14:6,926,972...6,933,079
Ensembl chr14:6,926,976...6,933,070
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
multiple interactions decreases expression |
ISO |
[Manganese co-treated with Lipopolysaccharides] results in decreased expression of DUSP1 mRNA; [Manganese co-treated with Lipopolysaccharides] results in decreased expression of DUSP1 protein Manganese results in decreased expression of DUSP1 mRNA; Manganese results in decreased expression of DUSP1 protein |
CTD |
PMID:20589745 |
|
NCBI chr10:16,970,642...16,973,425
Ensembl chr10:16,970,626...16,973,418
|
|
G |
Eif2a |
eukaryotic translation initiation factor 2A |
increases expression |
ISO |
Manganese results in increased expression of EIF2A protein |
CTD |
PMID:21477646 |
|
NCBI chr 2:148,722,343...148,755,781
Ensembl chr 2:148,722,231...148,755,520
|
|
G |
Eif2ak2 |
eukaryotic translation initiation factor 2-alpha kinase 2 |
multiple interactions |
EXP |
[manganese chloride results in increased abundance of Manganese] which results in increased cleavage of EIF2AK2 protein; GW 506033X inhibits the reaction [[manganese chloride results in increased abundance of Manganese] which results in increased cleavage of EIF2AK2 protein]; pyrazolanthrone inhibits the reaction [[manganese chloride results in increased abundance of Manganese] which results in increased cleavage of EIF2AK2 protein] |
CTD |
PMID:32574669 |
|
NCBI chr 6:1,428,845...1,466,193
Ensembl chr 6:1,428,834...1,466,201
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
EXP |
[manganese chloride results in increased abundance of Manganese] which results in increased phosphorylation of EIF2AK3 protein |
CTD |
PMID:32574669 |
|
NCBI chr 4:98,648,513...98,709,695
Ensembl chr 4:98,648,545...98,709,694
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
multiple interactions |
EXP |
[manganese chloride results in increased abundance of Manganese] which results in increased phosphorylation of EIF2S1 protein |
CTD |
PMID:32574669 |
|
NCBI chr 6:102,048,372...102,073,041
Ensembl chr 6:102,048,372...102,073,041
|
|
G |
Elf1 |
E74 like ETS transcription factor 1 |
decreases expression |
ISO |
Manganese results in decreased expression of ELF1 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr15:61,772,544...61,868,442
Ensembl chr15:61,826,711...61,868,343
|
|
G |
Eml2 |
EMAP like 2 |
increases expression |
ISO |
Manganese results in increased expression of EML2 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 1:80,087,684...80,118,784
Ensembl chr 1:80,087,684...80,119,012
|
|
G |
Eno1 |
enolase 1 |
decreases activity |
ISO |
Manganese results in decreased activity of ENO1 protein |
CTD |
PMID:22191580 |
|
NCBI chr 5:167,288,223...167,299,610
Ensembl chr 5:167,288,223...167,299,609
|
|
G |
Epo |
erythropoietin |
increases glycosylation |
ISO |
Manganese results in increased glycosylation of EPO protein |
CTD |
PMID:16937399 |
|
NCBI chr12:22,274,828...22,278,268
Ensembl chr12:22,274,828...22,278,266
|
|
G |
Ercc6l |
ERCC excision repair 6 like, spindle assembly checkpoint helicase |
decreases expression |
ISO |
Manganese results in decreased expression of ERCC6L mRNA |
CTD |
PMID:17175027 |
|
NCBI chr X:72,018,373...72,034,140
Ensembl chr X:72,018,373...72,034,099
|
|
G |
Ereg |
epiregulin |
increases expression |
ISO |
Manganese results in increased expression of EREG mRNA |
CTD |
PMID:17175027 |
|
NCBI chr14:18,577,620...18,591,395
Ensembl chr14:18,576,355...18,591,394
|
|
G |
Erich1 |
glutamate-rich 1 |
increases expression |
ISO |
Manganese results in increased expression of ERICH1 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr16:80,601,873...80,667,774
Ensembl chr16:80,601,973...80,667,781
|
|
G |
Esr1 |
estrogen receptor 1 |
increases expression |
EXP |
Manganese results in increased expression of ESR1 protein |
CTD |
PMID:24845367 |
|
NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
|
|
G |
Exoc6 |
exocyst complex component 6 |
decreases expression |
ISO |
Manganese results in decreased expression of EXOC6 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 1:256,211,879...256,369,318
Ensembl chr 1:256,226,179...256,368,813
|
|
G |
Eya4 |
EYA transcriptional coactivator and phosphatase 4 |
decreases expression |
ISO |
Manganese results in decreased expression of EYA4 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 1:23,237,617...23,611,580
Ensembl chr 1:23,409,408...23,610,164
|
|
G |
F2 |
coagulation factor II |
multiple interactions increases uptake |
ISO |
1-Methyl-3-isobutylxanthine inhibits the reaction [F2 protein results in increased uptake of Manganese]; Colforsin inhibits the reaction [F2 protein results in increased uptake of Manganese]; Nickel inhibits the reaction [F2 protein results in increased uptake of Manganese]; Tetradecanoylphorbol Acetate inhibits the reaction [F2 protein results in increased uptake of Manganese] |
CTD |
PMID:2125206 |
|
NCBI chr 3:80,529,468...80,542,993
Ensembl chr 3:80,529,428...80,543,031
|
|
G |
Fa2h |
fatty acid 2-hydroxylase |
increases expression |
EXP |
Manganese results in increased expression of FA2H mRNA |
CTD |
PMID:26745496 |
|
NCBI chr19:43,545,380...43,596,788
Ensembl chr19:43,545,378...43,596,801
|
|
G |
Fam107a |
family with sequence similarity 107, member A |
decreases expression |
EXP |
Manganese results in decreased expression of FAM107A mRNA |
CTD |
PMID:26745496 |
|
NCBI chr15:18,399,145...18,415,959
Ensembl chr15:18,399,515...18,415,965
|
|
G |
Fam180a |
family with sequence similarity 180, member A |
decreases expression |
EXP |
Manganese results in decreased expression of FAM180A mRNA |
CTD |
PMID:26745496 |
|
NCBI chr 4:62,845,054...62,860,361
Ensembl chr 4:62,844,971...62,860,446
|
|
G |
Fancf |
FA complementation group F |
decreases expression |
ISO |
Manganese results in decreased expression of FANCF mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 1:107,229,516...107,232,321
Ensembl chr 1:107,231,292...107,232,305
|
|
G |
Fcgr1a |
Fc fragment of IgG receptor Ia |
decreases expression |
EXP |
Manganese results in decreased expression of FCGR1A mRNA |
CTD |
PMID:26745496 |
|
NCBI chr 2:198,430,536...198,439,453
Ensembl chr 2:198,430,530...198,458,041
|
|
G |
Fgfbp1 |
fibroblast growth factor binding protein 1 |
decreases expression |
EXP |
Manganese results in decreased expression of FGFBP1 mRNA |
CTD |
PMID:26745496 |
|
NCBI chr14:71,647,429...71,650,359
Ensembl chr14:71,649,274...71,650,354
|
|
G |
Fhl1 |
four and a half LIM domains 1 |
decreases expression |
ISO |
Manganese results in decreased expression of FHL1 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr X:159,112,516...159,172,528
Ensembl chr X:159,112,880...159,172,524
|
|
G |
Fibin |
fin bud initiation factor homolog |
increases expression |
ISO |
Manganese results in increased expression of FIBIN mRNA |
CTD |
PMID:21615908 |
|
NCBI chr 3:101,545,207...101,547,478
Ensembl chr 3:101,545,208...101,547,478
|
|
G |
Flcn |
folliculin |
increases expression |
ISO |
Manganese results in increased expression of FLCN mRNA |
CTD |
PMID:17175027 |
|
NCBI chr10:46,153,185...46,172,331
Ensembl chr10:46,153,188...46,172,309
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions decreases expression |
EXP ISO |
[Curcumin co-treated with Manganese] inhibits the reaction [Kainic Acid results in increased expression of FOS protein]; [diacetylcurcumin co-treated with Manganese] inhibits the reaction [Kainic Acid results in increased expression of FOS protein] Manganese promotes the reaction [Tetradecanoylphorbol Acetate results in increased activity of [JUN protein binds to FOS protein]]; Manganese promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of FOS protein] Manganese results in decreased expression of FOS protein |
CTD |
PMID:17043766 PMID:17827730 PMID:22561169 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Foxn4 |
forkhead box N4 |
increases expression |
EXP |
Manganese results in increased expression of FOXN4 mRNA |
CTD |
PMID:26745496 |
|
NCBI chr12:48,101,012...48,121,281
Ensembl chr12:48,101,673...48,121,270
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions affects localization |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Manganese results in increased phosphorylation of FOXO3 protein]; 2-oxothiazolidine-4-carboxylic acid inhibits the reaction [Manganese affects the localization of FOXO3 protein]; 2-oxothiazolidine-4-carboxylic acid inhibits the reaction [Manganese results in increased expression of FOXO3 protein]; Manganese results in increased expression of and results in increased phosphorylation of FOXO3 protein; SB 203580 inhibits the reaction [Manganese results in increased phosphorylation of FOXO3 protein] |
CTD |
PMID:24787138 |
|
NCBI chr20:46,428,078...46,519,156
Ensembl chr20:46,428,124...46,519,144
|
|
G |
Foxp2 |
forkhead box P2 |
increases expression |
ISO |
Manganese results in increased expression of FOXP2 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 4:41,364,441...41,944,685
Ensembl chr 4:41,364,441...41,942,023
|
|
G |
Fth1 |
ferritin heavy chain 1 |
decreases expression increases expression |
EXP |
Manganese results in decreased expression of FTH1 mRNA; Manganese results in decreased expression of FTH1 protein Manganese results in increased expression of FTH1 protein |
CTD |
PMID:16545456 PMID:16568477 PMID:16740617 PMID:17469137 |
|
NCBI chr 1:226,030,940...226,033,228
Ensembl chr 1:226,030,938...226,033,228
|
|
G |
Fxyd2 |
FXYD domain-containing ion transport regulator 2 |
increases expression |
ISO |
Manganese results in increased expression of FXYD2 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 8:49,710,334...49,717,492
Ensembl chr 8:49,710,477...49,716,955
|
|
G |
Gabbr2 |
gamma-aminobutyric acid type B receptor subunit 2 |
multiple interactions |
ISO |
[manganese chloride results in increased abundance of Manganese] which results in increased expression of GABBR2 protein |
CTD |
PMID:32659473 |
|
NCBI chr 5:62,276,100...62,621,737
Ensembl chr 5:62,276,100...62,621,737
|
|
G |
Gabra1 |
gamma-aminobutyric acid type A receptor subunit alpha 1 |
multiple interactions |
ISO |
[manganese chloride results in increased abundance of Manganese] which results in decreased expression of GABRA1 protein |
CTD |
PMID:32659473 |
|
NCBI chr10:27,310,718...27,371,802
Ensembl chr10:27,310,725...27,366,665
|
|
G |
Gabrg2 |
gamma-aminobutyric acid type A receptor subunit gamma 2 |
increases expression |
ISO |
Manganese results in increased expression of GABRG2 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr10:27,090,913...27,179,786
Ensembl chr10:27,092,827...27,179,900
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
increases expression |
ISO |
Manganese results in increased expression of GADD45A mRNA |
CTD |
PMID:23499988 |
|
NCBI chr 4:97,782,512...97,784,814
Ensembl chr 4:97,782,512...97,784,842
|
|
G |
Gal |
galanin and GMAP prepropeptide |
increases expression |
ISO |
Manganese results in increased expression of GAL mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 1:218,653,059...218,657,922
Ensembl chr 1:218,652,917...218,657,925
|
|
G |
Gcfc2 |
GC-rich sequence DNA-binding factor 2 |
decreases expression |
ISO |
Manganese results in decreased expression of GCFC2 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 4:112,662,556...112,700,505
Ensembl chr 4:112,662,609...112,699,711
|
|
G |
Gdap2 |
ganglioside-induced differentiation-associated-protein 2 |
increases expression |
ISO |
Manganese results in increased expression of GDAP2 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 2:202,470,485...202,526,849
Ensembl chr 2:202,470,487...202,526,849
|
|
G |
Gdf15 |
growth differentiation factor 15 |
increases expression |
ISO |
Manganese results in increased expression of GDF15 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr16:20,555,395...20,557,978
Ensembl chr16:20,555,395...20,557,978
|
|
G |
Gfap |
glial fibrillary acidic protein |
decreases expression affects expression increases expression |
EXP ISO |
Manganese results in decreased expression of GFAP mRNA Manganese affects the expression of GFAP protein Manganese results in increased expression of GFAP mRNA; Manganese results in increased expression of GFAP protein |
CTD |
PMID:19782702 PMID:20224926 PMID:23832297 PMID:24885898 |
|
NCBI chr10:90,990,762...90,999,435
Ensembl chr10:90,990,762...90,999,506
|
|
G |
Gja5 |
gap junction protein, alpha 5 |
decreases expression |
EXP |
Manganese results in decreased expression of GJA5 mRNA |
CTD |
PMID:26745496 |
|
NCBI chr 2:199,162,745...199,184,942
Ensembl chr 2:199,162,745...199,184,939
|
|
G |
Gldn |
gliomedin |
decreases expression |
EXP |
Manganese results in decreased expression of GLDN mRNA |
CTD |
PMID:26745496 |
|
NCBI chr 8:58,870,516...58,914,605
Ensembl chr 8:58,870,516...58,914,603
|
|
G |
Glud1 |
glutamate dehydrogenase 1 |
decreases expression multiple interactions |
ISO |
Manganese deficiency results in decreased expression of GLUD1 protein Paroxetine inhibits the reaction [Manganese deficiency results in decreased expression of GLUD1 protein] |
CTD |
PMID:21312047 |
|
NCBI chr16:10,661,486...10,695,557
Ensembl chr16:10,662,021...10,695,557
|
|
G |
Glul |
glutamate-ammonia ligase |
affects expression decreases expression |
EXP |
Manganese affects the expression of GLUL mRNA; Manganese affects the expression of GLUL protein Manganese results in decreased expression of GLUL mRNA; Manganese results in decreased expression of GLUL protein |
CTD |
PMID:16842851 PMID:16943606 |
|
NCBI chr13:71,331,052...71,340,207
Ensembl chr13:71,331,052...71,340,229
|
|
G |
Gnrh1 |
gonadotropin releasing hormone 1 |
increases expression |
EXP |
Manganese results in increased expression of GNRH1 mRNA |
CTD |
PMID:23997110 |
|
NCBI chr15:44,441,856...44,446,064
Ensembl chr15:44,442,555...44,442,875 Ensembl chr15:44,442,555...44,442,875
|
|
G |
Gper1 |
G protein-coupled estrogen receptor 1 |
multiple interactions |
EXP |
[1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone binds to and results in increased activity of GPER1 protein] which results in decreased susceptibility to Manganese |
CTD |
PMID:22645130 |
|
NCBI chr12:17,309,122...17,315,267
Ensembl chr12:17,309,834...17,311,112
|
|
G |
Gpr18 |
G protein-coupled receptor 18 |
decreases expression |
EXP |
Manganese results in decreased expression of GPR18 mRNA |
CTD |
PMID:26745496 |
|
NCBI chr15:108,323,157...108,326,907
Ensembl chr15:108,323,179...108,326,907
|
|
G |
Gpr34 |
G protein-coupled receptor 34 |
decreases expression |
EXP |
Manganese results in decreased expression of GPR34 mRNA |
CTD |
PMID:26745496 |
|
NCBI chr X:10,022,986...10,043,504
Ensembl chr X:10,023,489...10,031,167
|
|
G |
Grin1 |
glutamate ionotropic receptor NMDA type subunit 1 |
decreases expression |
EXP |
Manganese results in decreased expression of GRIN1 mRNA; Manganese results in decreased expression of GRIN1 protein |
CTD |
PMID:19643132 PMID:29205667 |
|
NCBI chr 3:2,507,745...2,534,664
Ensembl chr 3:2,506,896...2,534,663
|
|
G |
Grin2a |
glutamate ionotropic receptor NMDA type subunit 2A |
decreases expression |
EXP |
Manganese results in decreased expression of GRIN2A mRNA; Manganese results in decreased expression of GRIN2A protein |
CTD |
PMID:19643132 PMID:29205667 |
|
NCBI chr10:5,707,806...6,123,568
Ensembl chr10:5,930,298...6,119,990
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
decreases expression |
EXP |
Manganese results in decreased expression of GRIN2B mRNA; Manganese results in decreased expression of GRIN2B protein |
CTD |
PMID:19643132 PMID:29205667 |
|
NCBI chr 4:169,541,620...170,000,216
Ensembl chr 4:169,560,387...169,999,873
|
|
G |
Gsr |
glutathione-disulfide reductase |
decreases expression multiple interactions |
ISO EXP |
Manganese results in decreased expression of GSR mRNA [manganese chloride results in increased abundance of Manganese] which results in decreased activity of GSR protein [Arsenic co-treated with Cadmium co-treated with Lead co-treated with Mercury co-treated with Chromium co-treated with Nickel co-treated with Manganese co-treated with Iron] results in decreased activity of GSR protein |
CTD |
PMID:17175027 PMID:17176674 PMID:32445656 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
affects response to substance |
ISO |
GSTP1 gene polymorphism affects the susceptibility to Manganese |
CTD |
PMID:30930959 |
|
NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
|
|
G |
Gtf2h1 |
general transcription factor IIH subunit 1 |
decreases expression |
ISO |
Manganese results in decreased expression of GTF2H1 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 1:102,849,618...102,877,939
Ensembl chr 1:102,849,889...102,877,944
|
|
G |
Gucy1a1 |
guanylate cyclase 1 soluble subunit alpha 1 |
multiple interactions |
ISO |
Manganese results in increased activity of [GUCY1A1 protein binds to GUCY1B1 protein] |
CTD |
PMID:22171090 |
|
NCBI chr 2:181,045,694...181,103,321
Ensembl chr 2:181,045,703...181,102,918
|
|
G |
Gucy1b1 |
guanylate cyclase 1 soluble subunit beta 1 |
multiple interactions |
ISO |
Manganese results in increased activity of [GUCY1A1 protein binds to GUCY1B1 protein] |
CTD |
PMID:22171090 |
|
NCBI chr 2:180,976,939...181,026,001
Ensembl chr 2:180,976,939...181,026,024
|
|
G |
Hamp |
hepcidin antimicrobial peptide |
decreases expression |
ISO |
Manganese results in decreased expression of HAMP mRNA |
CTD |
PMID:29020610 |
|
NCBI chr 1:89,368,021...89,369,960
Ensembl chr 1:89,368,021...89,369,960
|
|
G |
Hdac1 |
histone deacetylase 1 |
multiple interactions |
EXP |
Manganese promotes the reaction [RELA protein binds to HDAC1 protein]; Manganese promotes the reaction [YY1 protein binds to HDAC1 protein] |
CTD |
PMID:24469401 |
|
NCBI chr 5:147,716,664...147,743,723
Ensembl chr 5:147,716,664...147,743,723
|
|
G |
Heph |
hephaestin |
increases expression |
ISO |
Manganese results in increased expression of HEPH mRNA |
CTD |
PMID:17175027 |
|
NCBI chr X:65,377,313...65,658,479
Ensembl chr X:65,563,122...65,658,516
|
|
G |
Hfe |
homeostatic iron regulator |
affects abundance |
ISO |
HFE protein affects the abundance of Manganese |
CTD |
PMID:18317567 |
|
NCBI chr17:43,661,276...43,669,327
Ensembl chr17:43,661,222...43,669,985
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions increases expression |
ISO |
Manganese results in increased expression of and results in increased activity of HIF1A protein Manganese results in increased expression of HIF1A mRNA |
CTD |
PMID:16386771 PMID:17175027 |
|
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
|
|
G |
Hif1an |
hypoxia inducible factor 1 subunit alpha inhibitor |
decreases expression |
ISO |
Manganese results in decreased expression of HIF1AN mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 1:264,309,214...264,319,269
Ensembl chr 1:264,309,214...264,319,267
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions increases activity |
EXP |
[Manganese co-treated with Bilirubin] results in decreased activity of HMGCR protein Manganese results in increased activity of HMGCR protein |
CTD |
PMID:12700418 |
|
NCBI chr 2:27,480,224...27,500,654
Ensembl chr 2:27,480,226...27,500,654
|
|
G |
Hmgcs2 |
3-hydroxy-3-methylglutaryl-CoA synthase 2 |
decreases expression |
EXP |
Manganese results in decreased expression of HMGCS2 mRNA |
CTD |
PMID:26745496 |
|
NCBI chr 2:200,452,623...200,480,785
Ensembl chr 2:200,452,624...200,479,423
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
ISO EXP |
Manganese results in increased expression of HMOX1 mRNA [manganese chloride results in increased abundance of Manganese] which results in increased expression of HMOX1 protein; GW 506033X promotes the reaction [[manganese chloride results in increased abundance of Manganese] which results in increased expression of HMOX1 protein] |
CTD |
PMID:11181820 PMID:18948096 PMID:23832297 PMID:32574669 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hoxb9 |
homeo box B9 |
decreases expression |
ISO |
Manganese results in decreased expression of HOXB9 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr10:84,119,772...84,124,963
Ensembl chr10:84,119,884...84,123,390
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression multiple interactions |
ISO EXP |
Manganese results in increased expression of HSPA5 protein [manganese chloride results in increased abundance of Manganese] which results in increased expression of HSPA5 mRNA |
CTD |
PMID:21477646 PMID:32574669 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
multiple interactions |
ISO |
[Manganese binds to N'-((2-hydroxyphenyl)carbonothioyl)pyridine-2-carbohydrazide] which results in increased expression of HSPA8 protein |
CTD |
PMID:16600465 |
|
NCBI chr 8:44,989,401...44,993,261
Ensembl chr 8:44,990,014...44,993,179
|
|
G |
Htr1a |
5-hydroxytryptamine receptor 1A |
multiple interactions |
EXP |
Manganese affects the reaction [Serotonin inhibits the reaction [N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide binds to HTR1A protein]]; Manganese inhibits the reaction [Guanosine Triphosphate affects the reaction [Serotonin binds to HTR1A protein]] |
CTD |
PMID:21126535 |
|
NCBI chr 2:36,246,628...36,247,896
Ensembl chr 2:36,246,628...36,247,896
|
|
G |
Htt |
huntingtin |
decreases uptake multiple interactions decreases response to substance decreases abundance |
ISO EXP |
HTT protein mutant form results in decreased uptake of Manganese Manganese results in decreased phosphorylation of and results in increased expression of HTT protein HTT protein mutant form inhibits the reaction [Manganese results in decreased expression of UBQLN1 protein]; HTT protein mutant form inhibits the reaction [Manganese results in increased expression of NEFL protein]; Manganese inhibits the reaction [HTT protein mutant form affects the expression of SAE1 protein] HTT gene mutant form results in decreased susceptibility to Manganese HTT gene mutant form results in decreased abundance of Manganese |
CTD |
PMID:19845833 PMID:20547568 PMID:22191580 PMID:25099302 |
|
NCBI chr14:81,105,139...81,254,637
Ensembl chr14:81,105,139...81,254,637
|
|
G |
Id2 |
inhibitor of DNA binding 2 |
increases expression |
ISO |
Manganese results in increased expression of ID2 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 6:44,360,077...44,361,908
Ensembl chr 6:44,348,501...44,363,915
|
|
G |
Idh3a |
isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha |
affects binding |
ISO |
Manganese binds to IDH3A protein |
CTD |
PMID:16737955 |
|
NCBI chr 8:59,164,601...59,183,899
Ensembl chr 8:59,164,572...59,183,908
|
|
G |
Idh3g |
isocitrate dehydrogenase (NAD(+)) 3 non-catalytic subunit gamma |
affects binding |
ISO |
Manganese binds to IDH3G protein |
CTD |
PMID:16737955 |
|
NCBI chr X:156,999,803...157,008,735
Ensembl chr X:156,999,826...157,008,733
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
EXP ISO |
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Manganese inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]]; 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Manganese promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Free Radicals]]; 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Manganese promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA]]; 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Manganese promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TNF mRNA]]; 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Manganese promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TNF protein]]; [Lipopolysaccharides co-treated with IFNG protein co-treated with Manganese] results in decreased abundance of Nitric Oxide; [pyrazolanthrone co-treated with Manganese] inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; [SB 203580 co-treated with Manganese] inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; [U 0126 co-treated with Manganese] inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Manganese inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Manganese promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Free Radicals]; Manganese promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased degradation of NFKBIA protein]; Manganese promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Manganese promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 protein]; Manganese promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TNF mRNA]; Manganese promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TNF protein]; Manganese promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased phosphorylation of MAPK1 protein]; Manganese promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased phosphorylation of MAPK3 protein]; pyrazolanthrone inhibits the reaction [Manganese promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA]]; pyrazolanthrone inhibits the reaction [Manganese promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TNF protein]]; SB 203580 inhibits the reaction [Manganese promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA]]; SB 203580 inhibits the reaction [Manganese promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TNF protein]]; U 0126 inhibits the reaction [Manganese promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA]]; U 0126 inhibits the reaction [Manganese promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TNF protein]] Manganese promotes the reaction [[TNF protein co-treated with IFNG protein] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]]; Manganese promotes the reaction [TNF protein co-treated with and results in increased chemical synthesis of IFNG protein co-treated with and results in increased chemical synthesis of Nitric Oxide]; Manganese promotes the reaction [TNF protein co-treated with and results in increased expression of IFNG protein co-treated with and results in increased expression of NOS2 mRNA]; Manganese promotes the reaction [TNF protein co-treated with and results in increased expression of IFNG protein co-treated with and results in increased expression of NOS2 protein]; NFKBIA protein affects the reaction [Manganese promotes the reaction [TNF protein co-treated with and results in increased chemical synthesis of IFNG protein co-treated with and results in increased chemical synthesis of Nitric Oxide]]; NFKBIA protein affects the reaction [Manganese promotes the reaction [TNF protein co-treated with and results in increased expression of IFNG protein co-treated with and results in increased expression of NOS2 mRNA]]; NFKBIA protein affects the reaction [Manganese promotes the reaction [TNF protein co-treated with and results in increased expression of IFNG protein co-treated with and results in increased expression of NOS2 protein]] |
CTD |
PMID:16168523 PMID:16488514 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions |
ISO |
IKBKB gene mutant form results in increased susceptibility to [manganese chloride results in increased abundance of Manganese] |
CTD |
PMID:32692843 |
|
NCBI chr16:74,177,233...74,230,809
Ensembl chr16:74,177,215...74,230,815
|
|
G |
Il12a |
interleukin 12A |
increases expression |
ISO |
Manganese results in increased expression of IL12A mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 2:165,076,945...165,083,996
Ensembl chr 2:165,076,607...165,084,318
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
EXP |
Manganese results in increased expression of IL1B mRNA |
CTD |
PMID:19782702 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il1rl1 |
interleukin 1 receptor-like 1 |
decreases expression |
EXP |
Manganese results in decreased expression of IL1RL1 mRNA |
CTD |
PMID:26745496 |
|
NCBI chr 9:47,133,483...47,184,316
Ensembl chr 9:47,134,034...47,182,170
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
Manganese promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL2 mRNA]; Manganese promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL2 protein] |
CTD |
PMID:22561169 |
|
NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
|
|
G |
Il6 |
interleukin 6 |
increases expression increases uptake multiple interactions increases secretion |
ISO EXP |
Manganese results in increased expression of IL6 mRNA; Manganese results in increased expression of IL6 protein IL6 protein results in increased uptake of Manganese [IL6 protein results in decreased expression of SLC30A10 mRNA] which results in decreased export of Manganese; [IL6 protein results in decreased expression of SLC30A10 protein] which results in decreased export of Manganese Manganese results in increased secretion of IL6 protein [Manganese co-treated with Lipopolysaccharides] results in increased expression of IL6 mRNA |
CTD |
PMID:17065364 PMID:19263519 PMID:20224926 PMID:20589745 PMID:24576911 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Il7 |
interleukin 7 |
increases expression |
ISO |
Manganese results in increased expression of IL7 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 2:96,427,884...96,474,979
Ensembl chr 2:96,439,286...96,474,977
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
[manganese chloride results in increased abundance of Manganese] inhibits the reaction [Glucose results in increased secretion of INS protein]; [Manganese co-treated with Magnesium co-treated with INS protein] results in increased phosphorylation of and results in increased activity of INSR protein; [Polylysine co-treated with Manganese co-treated with Magnesium] promotes the reaction [INS protein results in increased phosphorylation of and results in increased activity of INSR protein modified form]; [Polylysine co-treated with Manganese co-treated with Magnesium] promotes the reaction [INS protein results in increased phosphorylation of and results in increased activity of INSR protein] |
CTD |
PMID:2542339 PMID:31555879 |
|
NCBI chr 1:215,856,967...215,858,034
Ensembl chr 1:215,856,971...215,858,034
|
|
G |
Insr |
insulin receptor |
multiple interactions decreases expression |
EXP ISO |
[Manganese co-treated with INS1 protein] results in increased phosphorylation of INSR protein Manganese deficiency results in decreased expression of INSR protein [Manganese co-treated with Magnesium co-treated with INS protein] results in increased phosphorylation of and results in increased activity of INSR protein; [Polylysine co-treated with Manganese co-treated with Magnesium] promotes the reaction [INS protein results in increased phosphorylation of and results in increased activity of INSR protein modified form]; [Polylysine co-treated with Manganese co-treated with Magnesium] promotes the reaction [INS protein results in increased phosphorylation of and results in increased activity of INSR protein] |
CTD |
PMID:1321133 PMID:2204694 PMID:2542339 |
|
NCBI chr12:1,682,527...1,816,414
Ensembl chr12:1,680,957...1,816,414
|
|
G |
Ireb2 |
iron responsive element binding protein 2 |
decreases activity increases expression |
EXP |
Manganese results in decreased activity of IREB2 protein Manganese results in increased expression of IREB2 protein |
CTD |
PMID:16568477 PMID:17469137 |
|
NCBI chr 8:59,450,974...59,503,634
Ensembl chr 8:59,420,123...59,501,118
|
|
G |
Irs4 |
insulin receptor substrate 4 |
multiple interactions |
EXP |
[Manganese co-treated with INS1 protein] results in increased phosphorylation of IRS4 protein |
CTD |
PMID:1321133 |
|
NCBI chr X:113,003,824...113,018,088
|
|
G |
Itga3 |
integrin subunit alpha 3 |
increases expression |
ISO |
Manganese results in increased expression of ITGA3 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr10:82,855,841...82,887,755
Ensembl chr10:82,855,613...82,887,497
|
|
G |
Itgam |
integrin subunit alpha M |
increases expression |
EXP |
Manganese results in increased expression of ITGAM mRNA |
CTD |
PMID:20224926 |
|
NCBI chr 1:199,495,312...199,545,738
Ensembl chr 1:199,495,298...199,623,960
|
|
G |
Itgb1 |
integrin subunit beta 1 |
increases activity |
EXP |
Manganese results in increased activity of ITGB1 protein |
CTD |
PMID:10820171 PMID:16606368 |
|
NCBI chr19:61,677,512...61,725,537
Ensembl chr19:61,677,542...61,725,535
|
|
G |
Itgb5 |
integrin subunit beta 5 |
increases expression |
ISO |
Manganese results in increased expression of ITGB5 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr11:70,056,500...70,172,164
Ensembl chr11:70,056,500...70,172,372
|
|
G |
Itih1 |
inter-alpha trypsin inhibitor, heavy chain 1 |
multiple interactions |
ISO |
Manganese promotes the reaction [ITIH1 protein binds to TNFAIP6 protein] |
CTD |
PMID:16768462 |
|
NCBI chr16:7,012,376...7,026,542
Ensembl chr16:7,012,354...7,026,540
|
|
G |
Itih2 |
inter-alpha-trypsin inhibitor heavy chain 2 |
multiple interactions |
ISO |
Manganese promotes the reaction [ITIH2 protein binds to TNFAIP6 protein] |
CTD |
PMID:16768462 |
|
NCBI chr17:72,160,734...72,197,248
Ensembl chr17:72,160,735...72,195,509
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
decreases expression multiple interactions |
ISO EXP |
Manganese results in decreased expression of JUN protein Manganese promotes the reaction [Tetradecanoylphorbol Acetate results in increased activity of [JUN protein binds to FOS protein]]; Manganese promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of JUN protein]; Manganese promotes the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of JUN protein] [Curcumin co-treated with Manganese] inhibits the reaction [Kainic Acid results in increased expression of JUN mRNA]; [diacetylcurcumin co-treated with Manganese] inhibits the reaction [Kainic Acid results in increased expression of JUN mRNA]; NEPP11 compound inhibits the reaction [Manganese results in increased phosphorylation of JUN protein] |
CTD |
PMID:15342272 PMID:17043766 PMID:17827730 PMID:22561169 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Kcnip3 |
potassium voltage-gated channel interacting protein 3 |
increases expression |
ISO |
Manganese results in increased expression of KCNIP3 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 3:120,023,062...120,087,650
Ensembl chr 3:120,023,917...120,087,136
|
|
G |
Kcnj11 |
potassium inwardly-rectifying channel, subfamily J, member 11 |
multiple interactions |
ISO |
KCNJ11 protein affects the reaction [[Manganese co-treated with Dobutamine] results in increased abundance of Calcium] [manganese chloride results in increased abundance of Manganese] which results in decreased expression of KCNJ11 protein |
CTD |
PMID:17189350 PMID:32659473 |
|
NCBI chr 1:102,103,093...102,107,134
Ensembl chr 1:102,103,094...102,106,127
|
|
G |
Kcnj3 |
potassium inwardly-rectifying channel, subfamily J, member 3 |
increases expression |
ISO |
Manganese results in increased expression of KCNJ3 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 3:41,019,898...41,181,070
Ensembl chr 3:41,019,898...41,181,070
|
|
G |
Kcnj8 |
potassium inwardly-rectifying channel, subfamily J, member 8 |
multiple interactions |
ISO |
[manganese chloride results in increased abundance of Manganese] which results in decreased expression of KCNJ8 protein |
CTD |
PMID:32659473 |
|
NCBI chr 4:176,783,287...176,789,143
Ensembl chr 4:176,782,498...176,789,304
|
|
G |
Kera |
keratocan |
increases expression |
EXP |
Manganese results in increased expression of KERA mRNA |
CTD |
PMID:26745496 |
|
NCBI chr 7:38,858,062...38,865,515
Ensembl chr 7:38,858,062...38,865,515
|
|
G |
Khsrp |
KH-type splicing regulatory protein |
multiple interactions increases expression |
EXP |
KHSRP protein affects the reaction [Manganese results in increased expression of TP53 protein] Manganese results in increased expression of KHSRP protein |
CTD |
PMID:25027559 |
|
NCBI chr 9:10,013,795...10,023,670
Ensembl chr 9:10,013,854...10,022,924
|
|
G |
Kiss1 |
KiSS-1 metastasis-suppressor |
increases expression |
EXP |
Manganese results in increased expression of KISS1 mRNA |
CTD |
PMID:23997110 |
|
NCBI chr13:50,529,506...50,537,603
Ensembl chr13:50,529,510...50,535,389
|
|
G |
Kiss1r |
KISS1 receptor |
increases expression |
EXP |
Manganese results in increased expression of KISS1R mRNA |
CTD |
PMID:23997110 |
|
NCBI chr 7:12,606,210...12,609,868
Ensembl chr 7:12,606,210...12,609,868
|
|
G |
Klf4 |
Kruppel like factor 4 |
increases expression |
ISO |
Manganese results in increased expression of KLF4 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 5:72,283,311...72,287,669
Ensembl chr 5:72,283,313...72,287,669
|
|
G |
Klf9 |
Kruppel-like factor 9 |
decreases expression |
ISO |
Manganese results in decreased expression of KLF9 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 1:240,908,483...240,933,198
Ensembl chr 1:240,908,483...240,933,198
|
|
G |
Ldhb |
lactate dehydrogenase B |
affects expression |
EXP |
Manganese affects the expression of LDHB protein |
CTD |
PMID:24885898 |
|
NCBI chr 4:176,701,980...176,719,999
Ensembl chr 4:176,701,983...176,720,012
|
|
G |
Lep |
leptin |
decreases abundance |
ISO |
LEP gene mutant form results in decreased abundance of Manganese |
CTD |
PMID:10965932 |
|
NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
|
|
G |
Lman2 |
lectin, mannose-binding 2 |
increases expression |
ISO |
Manganese results in increased expression of LMAN2 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr17:9,798,136...9,815,820
Ensembl chr17:9,797,907...9,816,139
|
|
G |
LOC100360841 |
ribosomal protein L37-like |
decreases expression |
ISO |
Manganese results in decreased expression of RPL37 mRNA |
CTD |
PMID:27329587 |
|
NCBI chr 9:69,790,829...69,791,199
Ensembl chr 9:69,790,831...69,791,196
|
|
G |
LOC100911804 |
apolipoprotein L3-like |
increases expression |
ISO |
Manganese results in increased expression of APOL2 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 7:118,979,230...118,986,699
Ensembl chr 7:118,979,608...118,983,984
|
|
G |
Lrat |
lecithin retinol acyltransferase |
increases expression |
EXP |
Manganese results in increased expression of LRAT mRNA |
CTD |
PMID:26745496 |
|
NCBI chr 2:181,896,304...181,905,366
Ensembl chr 2:181,896,305...181,905,300
|
|
G |
Lrrk2 |
leucine-rich repeat kinase 2 |
increases response to substance multiple interactions |
ISO |
LRRK2 mutant form results in increased susceptibility to Manganese LRRK2 mutant form results in increased susceptibility to [Manganese co-treated with SLC6A3 protein] |
CTD |
PMID:23628791 |
|
NCBI chr 7:132,857,311...133,018,549
Ensembl chr 7:132,857,628...133,018,584
|